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Abstract 
All chronic liver diseases can induce fibrosis and lead to liver cirrhosis. Within liver disease, 
hepatic stellate cells (HSC) are accepted as the major effectors of fibrogenesis and changes 
in the extracellular matrix (ECM). Cytoglobin (CYGB), a hexacoordinated globin, is 
upregulated in liver disease, and expression has been reported to be specific to HSCs in the 
liver, though this is disputed. Data presented in Chapter 3 of this thesis confirm upregulation 
of Cygb in murine models of liver disease and diseased human liver tissue. Chapter 4 shows 
how ECM can effect HSC morphology, behaviour and phenotype with collagen I, an 
important component of the hepatic scar conferring an activated HSC phenotype, and 
laminin, a basal protein in a normal liver, inducing a more quiescent phenotype in HSC cell 
lines HSC-T6 and LX-2. Chapter 5 demonstrates the novel observation of collagen I-induced 
downregulation, and laminin-induced upregulation, of Cygb in HSC-T6s. Chapter 6 explores 
the role of cell signalling through membrane receptors and regulation of Cygb expression, 
identifying phosphorylated focal adhesion kinase as a mechanism of signal transduction 
through integrin activation. These findings suggest that Cygb expression is modulated by 
‘outside-in signalling’ and this is important in the activation status of HSCs. 
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1.1 Cytoglobin 
1.1.1 Discovery 
 
Cytoglobin (Cygb) was discovered in a proteomic screen as a protein that was upregulated 
on in vivo activation of Hepatic Stellate Cells (HSCs),achieved by carbon tetrachloride (CCl4) 
injection (Kristensen et al., 2000). HSCs, hepatocytes, endothelial cells and kupffer cells 
were isolated from normal and fibrotic rat livers and subjected to proteomic analysis, which 
identified 17 novel, upregulated proteins between quiescent and activated HSCs. Further 
analysis by Kawada et al. (2001), investigating HSCs activated in vitro and in vivo, showed 
that one protein spot, previously identified by Kristensen et al., was notably upregulated 
both in vitro and in vivo on HSC activation. The DNA sequence of this protein was used as a 
probe, and a screen of an activated HSC complimentary DNA (cDNA) library of rat origin was 
conducted. A 2028bp (base pair) cDNA clone was found, with an open reading frame of 
570bp coding for 190 amino acids with a molecular weight of 21,496daltons. The amino acid 
sequence showed between 30% to 40% homology with myoglobin and there was evidence 
of cytoplasmic location according to Reinhardt’s criterion (Reinhardt and Hubbard, 1998, 
Kawada et al., 2001). This novel protein was named stellate cell activation protein or ‘STAP’, 
as it was discovered to be time independently induced when HSC were activated in vitro and 
in vivo. Homologues to rat STAP cDNA in human and mouse cDNA libraries were identified, 
sharing 94% and 97% amino acid sequence identity to rat STAP respectively. Human and rat 
STAP were found to contain two histidine residues at positions 81 and 113 from the N-
terminus and it was suggested these residues could be involved in haem binding sites. 
Analysis revealed that the human STAP gene comprised four exons on chromosome 17q and 
that its mRNA is expressed in the normal adult brain, heart, kidney, lung, trachea, liver and 
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placenta. In culture HSCs and HepG2 (a human hepatocellular carcinoma cell line) cells 
express human STAP mRNA and STAP positive cells have occasionally observed around bile 
ducts (Kawada and Le, 2011). STAP was renamed cytoglobin (CYGB) by Burmester et 
al.(2002) after several reports showed ubiquitous expression in human tissue and in a wide 
range murine tissue and organs, Trent and Hargrove (2002) named CYGB ‘Histoglobin’ as it is 
expressed in a wide range of tissues, however CYGB has become the recognised 
nomenclature for this globin in the scientific literature. 
 
1.1.2 The globin family 
 
Proteins containing a haem group are generally referred to as globins, and globins in general 
bind gaseous diatomic ligands using an iron containing porphyrin ring. Globins have been 
identified in archea, bacteria, protists, plants, fungi and animals (Hardison, 1996, Hardison, 
1998). There are four main types of vertebrate globin, which have different tissue 
distribution and function, haemoglobin (HB), myoglobin (MB), neuroglobin (NGB) and CYGB 
(Schmidt et al., 2004), but it has recently been reported that the vertebrate globin family 
contains at least eight constituents, all with distinct features (Shivapurkar et al., 2008). 
Globin proteins are characterised by a fold of six to eight α helices (Figure 1.1 A) and a haem 
group comprised of Fe2+ -protoporphyrin IX (Figure 1.1 B)(Murzin et al., 1995) and the globin 
fold is highly evolutionarily conserved (Bashford et al., 1987). The structure of the globin 
fold seen in CYGB is indistinguishable from the globin folds of Hb and Mb, despite their low 
overall amino acid sequence identities (Makino et al., 2011). 
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Figure 1.1: A): An example of an eight helices globin fold showing helices A-H, image availableunder the Creative 
Commons Attribution-Share Alike license 3.0 http://creativecommons.org/licenses/by-sa/3.0/deed.en, attribution : 
Opabinia regalis, source: Wikicommons. B) A representation of Fe
2+ 
protoporphyrin IX haem group. Image in public 
domain, source: Wikicomons. 
B
 
C 
D 
A 
G 
E 
F 
G 
B
 
A 
5 
 
1.1.2.1 Evolutionary history of CYGB 
 
Much debate and discussion exists around the evolution of CYGB, it has been found in 
all vertebrates studied so far, and some reports suggest that it is an ancestral globin 
(Pesce et al., 2002, Shivapurkar et al., 2008), indicating a primitive and vital function 
(Fago et al., 2004). There are many reports analysing the evolution of CYGB and new 
data are frequently being published; however, currently there is no consensus on 
CYGB’s phylogenetic relationship with other globins within the vertebrate phylogenetic 
tree (Goodman et al., 1987, Benton, 1990, Burmester et al., 2002, Pesce et al., 2002, 
Hankeln et al., 2005, Shivapurkar et al., 2008). 
 
1.1.2.2 CYGB in comparison with other globins 
 
Globins are typically thought of as respiratory proteins involved in respiratory chain 
metabolism, but they can also have enzymatic functions and undergo redox reactions 
(for example Hb undergoes redox reactions forming ferric [Fe+3] and ferryl [Fe+4] Hb) 
they are also involved in and oxygen transport (Dickerson and Geis, 1983, Bunn and 
Forget, 1986, Brunori, 1999, Minning et al., 1999, Merx et al., 2001 ). CYGB shares 
common sequence structures with the other human globins; such as the invariant 
proximal HisF8 and PheCD1, and the distil HisE7, and is most closely related to Mb 
amongst the human globins, with similar haem pocket amino acid sequence and O2 
and CO affinities —the association of ligands in CYGB is faster than MB, but ligand 
dissociation slower, and therefore the overall equilibrium constants for O2 and CO in 
MB and CYGB are similar. Spectroscopic analysis of reduced deoxygenated CYGB 
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distinguishes it from MB though. Ligand association rates for CYGB are slower than 
that of NGB for both oxygen and histidine (Makino et al., 2011).  
 
1.1.3 The structure of CYGB 
 
The mammalian CYGB protein is longer than mammalian HB, MB and NGB at 190 
amino acids, compared with the 140 – 160 amino acids, which is typical of the other 
human globins — MB and HB are approximately 150 amino acids long. CYGB is 190 
amino acids due to the unusually long N- and C- termini. These termini extensions 
change the hydrodynamic properties of CYGB compared with other globins by 
increasing its hydrodynamic diameter to that of a dimer whilst retaining the mass of a 
monomer, they also contribute to interactions with neighbouring molecules of the 
protein crystal of CYGB (Makino et al., 2006, Lechauve et al., 2010). Similar extensions 
at the N- and C- termini have been observed in some invertebrate globins like 
Caenorhabditis elegans (Neuwald et al., 1997) but their functional relevance is not 
known. The N- terminus extension in murine and human CYGB might have been 
caused by a direct duplication of 21 nucleotides at the 5’ end of the coding region and 
the C- terminus extension could be due to the recruitment of an additional exon. Many 
globins, including vertebrate HB, MB and NGB contain the B12-2 (meaning, helix B, 
12th amino acid, between codon positions 2 and 3) and G7-0 introns present in CYGB, 
and are considered to be ancient in phylogenetic terms (Dixon and Pohajdak, 1992, 
Burmester et al., 2000). The identification of the most 3’ intron of the murine and 
human CYGB at the C- terminal position HC11-2 had not been seen in previous globin 
7 
 
structures, and the function of the 10 amino acid long exon sequence at the 3’ end, 
which is not present in chicken and fish, is uncertain, however, it has speculated that 
the C- and N- termini extensions may be involved in lipid binding (Burmester et al., 
2002, Burmester, 2004 #26, Reeder, 2011 #25). Between amino acid residues 18 to 71, 
which form the core of its structure, CYGB displays the 3-over-3 α helical sandwich 
common in other globins, the protoporphyrin IX prosthetic group is coordinated to the 
polypeptide chain by His 113 and His 81, proximally and distally, and sits between the 
E and F α helices (de Sanctis et al., 2004). 
Recombinant CYGB is a hexacoordinate haemoglobin (hxHb) in the deoxy form 
(Kawada et al., 2001, Asahina et al., 2002, Trent and Hargrove, 2002), and hxHbs have 
been discovered in animals, protists, cyanobacteria and plants (Arredondo-Peter et al., 
1998, Burmester et al., 2000, Scott and Lecomte, 2000, Awenius et al., 2001, Hvitved et 
al., 2001). Hexacoordinate haemoglobins potentially differ in physiological function 
from pentacoordinate haemoglobins like Hb and Mb, and use a different ligand binding 
mechanism which involves reversible intramolecular coordination of the haem iron, 
contrary to the previous belief that an open binding site is required for reversible 
ligand binding. hxHbs reversibly bind Oxygen (O2) as well as other haem ligands with 
relatively high affinities despite the apparent impediment (Hargrove, 2000). 
One of the two histidine side chains, which coordinate hxHb haem groups, is able to 
reversibly dissociate and, therefore, exogenous ligands can bind stably. The binding 
time, speed of association/dissociation of the coordinating histidine from the haem 
iron, and the equilibrium fraction of protein in the hexacoordinate state are influenced 
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by the distal histidine coordination (Hamdane et al., 2003, Smagghe et al., 2008). The 
affinity constant for histidine coordination is directly related to the effect of 
hexacoordination on equilibrium constants in hxHb binding (Trent et al., 2001, Trent 
and Hargrove, 2002).  
In the haem pocket of CYGB, His113 (F8) and His81 (E7) bind to the iron atom as fifth 
and sixth axial ligands respectively, before ligand binding in CYGB there needs to be 
dissociation of His81 and the binding of CO seems to be competitive with His81. CYGB 
has been shown to be able to form an intraprotein disulfide bridge, which affects the 
position of the E-helix, therefore modifies affinity for the distil histidine. O2 affinity is 
dependent on histidine binding, so disulfide bond formation affects O2 binding affinity. 
In CYGB the Cys E9 and His E7 are on opposite sides of the E-helix and the formation of 
a disulfide bond between Cys83(E9) and Cys38(B2) bond theoretically directly pulls on 
His E7, causing a conformational change and affect the molecular dynamics, 
influencing ligand binding (Lechauve et al., 2010). Recent research by Astudillo et al. 
(2013) has indicated that this disulfide bond between the B and E helices does indeed 
adjust the conformational dynamics of CYGB. The helices’ conformation alters 
dependending on the oxidation state of the Cys 38 and Cys 83 side chains, and 
disulfide bridge formation changes the migration pathway of ligands. Figure 1.2 shows 
the shift from hexacoordinate to pentacoordinate form in the haem pocket of CYGB.  
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Figure 1.2: Illustration of the distal and proximal regions of the CYGB haem binding site, overlaying the 
closed hexacoordinated form (blue haem and ribbons), and the open pentacoordinated form (ochre colour). 
From de Sanctis et al.(2004) with permission form Elseivier (license number 3527240919479). 
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Figure 1.3: The crystal protein structure of homodiamer of CYGB modified from http://www.rcsb.org/pdb 
access number 1UMO (de Sanctis et al., 2004).J.Mol.Biol. 336: 917-927). 
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There is some debate over the conformation of CYGB, chromatographic analysis of 
purified-recombinant CYGB has suggested it exists in a dimeric form (as is depicted in 
Figure 1.3), which is stable and not based on disulfide bonds; however, when the 
central globular fragment is eluted on its own, it appears to be monomeric. CYGB is 
monomeric in solution as measured by Multi-Angle Laser Light Scattering (MALLS) in 
the concentration range expected in vivo with possibility of an intramolecular disulfide 
bridge, which affects helices conformation, and therefore could affect function, as 
described above (Lechauve et al., 2010). Cysteine residues might be involved in the 
formation of intramolecular disulfide bonds, but early evidence suggested that 
truncated CYGB is monomeric (Hamdane et al., 2003). A CYGB dimer could be formed 
via one or two intermolecular disulphide bonds between two monomers, but only a 
small fraction of CYGB formed dimers observed in mass spectrometry (Lechauve et al., 
2010, Cabrita et al., 2011) . CYGB could possibly have haem-haem interactions, having 
Hill coefficients for co-operative binding of 0.63-1.63, which could be evidence for 
dimer formation (Fago et al., 2004). Most recently, Tsujino et al.(2014) have shown 
that CYGB exist in three different forms – monomeric, dimeric and tetrameric – and 
these three forms have different binding affinities for cyanide, and also CO in the when 
in the ferrous form. 
Reeder et al. (2011) observed that the optical spectrum for CYGB showed the haem 
iron in a low spin state - HisF8-Fe3+ –HisE7 coordination, and when the lipid oleate 
bound to ferric CYGB. The optical spectrum changed to a high spin state, and 
conformation of the haem changed from hexacoordinate to one consistent with a 
pentacoordinate haem like MB or HB - with water in the 6th coordinate, the same 
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phenomenon was observed with the lipid cardiolipin, but not with ferrous CYGB. 
Removing the intermolecular disulfide bridge appears to weaken the hexacoordination 
of CYGB, therefore, if CYGB exists in dimeric form, binding to one subunit of a CYGB 
dimer may influence the dissociation of the distil histidine from the iron of the other 
subunit, and have an effect on ligand binding. This could be important in the function 
of CYGB. Also this conformational change on binding with a lipid molecule in CYGB 
does not occur with other hexacoordinate haemoglobins like NGB, and may be a 
unique property of CYGB related to its function, such as the observed peroxidise 
activity discussed in 1.1.6.4. 
 
1.1.4 Genetics of Cygb 
 
In mammals CYGB is a single copy gene (Burmester et al., 2002) and its evolution 
appears to be complex with many subfunctionalisation events (Burmester et al., 2004). 
In humans it is mapped at the 17q25.3 chromosomal segment, where as in mice and 
rats it is on conserved syntenic segments (in the same chromosomal location) on 
chromosome MMU11E2 in mice and RNO10q32.2 in rats (Wystub et al., 2004). It has 
been suggested that CYGB and MB might have originated from an ancient 
chromosome duplication event, as the chromosome regions representing CYGB 
(17q25) and MB (22q12) have long paralogous stretches of genomic DNA (McLysaght 
et al., 2002), though if cygb is present in sea lampreys, as has been suggested, it 
diverged from the clade before mb (Shivapurkar et al., 2008), making it unlikely that 
cygb and mb arose from a duplication event. CYGB consists of three introns, two of 
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which are in conserved regions: B12-2  and G7-0, typical of all globin molecules. hxHbs 
like CYGB also possess a third intron, which it is positioned at H36-2 (Burmester et al., 
2002, Trent and Hargrove, 2002, Burmester et al., 2004).  
Mouse and human Cygb have 92.8% nucleotide sequence identity and 95.3% amino 
acid sequence identity in the coding region, where as only 49% amino acid identity is 
shared between mammalian and zebra fish Cygbs (Burmester et al., 2002). Cygbs show 
a high degree of amino acid sequence similarity to Hbs of Agnatha; between 26% and 
33%. The high degree of conservation indicates a vital structural function for Cygb, and 
an amino acid substitution rate of approximately 0.3 x 10-9 replacements per site per 
year for Cygb, based on the assumed divergence of mice and humans 80MYA (Kimura, 
1987), supports this theory. This substitution rate is substantially lower than those 
calculated for haemoglobins (0.9-1.2 x 10-9) and myoglobins (0.8-1.2 x 10-9) but is 
similar to the estimated substitution rate of Ngbs (0.4 x 10-9) (Burmester et al., 2002, 
Trent and Hargrove, 2002).  
 
1.1.4.1 Regulation of CYGB expression 
 
It has been reported that CYGB’s promoter region contains several transcription start 
points, a CpG island 1.4 kb in length, multiple CG boxes and Sp1 (stimulatory protein 1) 
binding sites, which might be recognised by transcription factors including Sp1, NFκB 
(nuclear factor kappa-light-chain-enhancer of activated B cells), Krupple-like zinc finger 
proteins, and motifs which are recognised by AP (activator protein) -1, AP-2, C/EBP 
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(CCAAT-enhancer-binding protein) and NF-1 (nuclear factor 1) – which are conserved 
in position and sequence in humans and mice, also two human, rat and mouse 
conserved hypoxia regulatory elements (HREs), two HIF1 (hypoxia inducible factor 1) 
binding sites and EPO (erythropoietin) box motifs, a c-Ets-1 (cellular erythroblastosis 
virus E26 oncogene homolog 1) binding site, a site recognised by NFAT (Nuclear factor 
of activated T-cells) and a conserved HIPBS (hypoxia inducible protein binding site) are 
present, notably, the CYGB gene doesn’t have a TATA box (Wystub et al., 2004, Guo et 
al., 2006). This collection of regulatory elements gives a strong indication that 
transcription of the CYGB gene is upregulated in hypoxic conditions (Shaw et al., 2009, 
Genin et al., 2008, Hockel and Vaupel, 2001). Upregulation of CYGB has been shown in 
vitro in glioblastoma (Emara et al., 2010) and in a neonatal rat model of hypoxia-
ischemia injury in the brain (Tian et al., 2013), the function of CYGB in hypoxic 
conditions is discussed in section 1.1.6.3. The presence of a CpG island, which 
encompasses regulatory factor binding sites present in the promoter, indicates that 
CYGB expression has the potential to be controlled epigenetically. Evidence for 
epigenetic control was observed by Shaw et al.(2007), who reported CpG promoter 
methylation for CYGB in the tumours of patients with oral squamous cell carcinoma. It 
has also been reported that c-Ets-1 is important in extracellular matrix (ECM) 
remodelling and its expression has been found to be critical to ECM composition in 
fibroblast cells (Hockel et al., 1996). Some of the regulatory elements present in 
CYGB’s promoter region are important in HSC modulation, overlapping elements are 
discussed in section 1.2.1.4, and the presence of these elements is suggestive of a role 
for CYGB in HSC activation. 
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Efficient transcription of CYGB is dependent on the region -1113 – 10 kb upstream of 
the ATG start codon, and the c-Ets-1 and Sp1 binding sites are critical for promoter 
activity in normoxic conditions (Guo et al., 2006) while the HIF1 and EPO binding 
motifs are crucial for CYGB regulation under hypoxic conditions (Guo et al., 
2007).Further analysis has indicated that AP-1 and NFAT are more important in CYGB 
transcription than HIF1, as part of a calcineurin mediated response, under hypoxic 
conditions in mouse hearts (Singh et al., 2009). Research by Nakatani et al.(2004) also 
indicates that CYGB transcription may be regulated by transforming growth factor β1 
(TGFβ1) and platelet derived growth factor-BB (PDGF-BB), which have been implicated 
in HSC activation (Reeves and Friedman, 2002). 
 
1.1.5 Localisation of CYGB 
 
CYGB is the most recent of the vertebrate globins to be identified, and with regards to 
its expression in human tissues, it was first reported as being ubiquitously expressed 
(Trent and Hargrove, 2002).It is present in many cell types myofibroblasts, osteoblasts, 
osteocytes, chondrocytes, fibroblasts, neurons of the peripheral and central nervous 
system and HSC (Kawada et al., 2001, Asahina et al., 2002, Nakatani et al., 2004, 
Schmidt et al., 2004), most recently CYGB has been identified in melanocytes and 
melanoma cells (Shaw et al., 2013). It has been identified in a range of tissues such as 
heart, muscle, colon, kidney, liver, tendon, brain and skin in mouse, rat and human 
(Schmidt et al., 2004). Research has indicated that CYGB expression is largely restricted 
to cells of a fibroblast lineage and some neurons in normal visceral organs. Cygb 
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positive cells have been observed in fibrotic tissue in fibroblast-like cells identified by 
morphological analysis (Nakatani et al., 2004, Schmidt et al., 2004). Schmidt et 
al.(2004) also reported that CYGB was not detected in hepatocytes or endothelial cells, 
sinusoidal and red blood cells, although its absence from hepatocytes is disputed, as 
others have reported observing CYGB in hepatocytes (Geuens et al., 2003, Yang et al., 
2011), the most recent study analysing CYGB localisation has reported hepatocytes in 
the human liver to be negative for CYGB expression (Motoyama et al., 2014).  
There is debate over the subcellular localisation of CYGB, Schmidt et al.(2004) reported 
that within HSCs, CYGB was detected in the cytoplasm but not in the nucleus. CYGB 
labelling in fibroblasts, chondroblasts, osteoblasts and osteocytes was uniformly 
distributed within the cytoplasm and cytoplasmic extensions. There was no staining 
observed within the extracellular matrix or nuclei of cells, however CYGB was seen in 
neurons of myenteric plexus in the colon where staining occurred in both cytoplasm 
and nuclei. Geuens et al. (2003), reported nuclear expression of Cygb in a range of 
tissues including mouse brain, renal glomerular cells and distil and proximal tubuli and 
pancreatic cells. Shigematsu et al.(2008) also reported nuclear expression in 
hepatocytes, and Man et al. (2008) observed cytoplasmic and some nuclear staining in 
liver fibroblasts, and specifically cytoplasmic and nuclear staining of HSCs, but no 
staining in hepatocytes, as well as cytoplasmic staining in fibroblasts of lung, kidney 
and thigh muscle. Recently, Singh et al. (2014) reported nuclear and cytoplasmic Cygb 
expression in muscle progenitor cells and proliferating myoblasts and Fujita et al. 
(2014) also observed Cygb expression in the nuclei and cytoplasm of melanocytes, so 
this issue of subcellular localisation of Cygb remains unresolved. Itoh et al. (2013) have 
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observed that the nuclear receptors Neuronal PAS domain protein 2 and REV-ERBα, 
which are known to bind haem (Raghuram et al., 2007, Ishida et al., 2008), could 
facilitate Cygb translocation to the nucleus in HEK293T cells and HeLa cells. Li et al. 
(2014) recently reported that REV-ERBα is upregulated in activated primary rat HSC 
and in injured liver in in vivo rat models and human liver tissue. Guo et al. (2006) found 
that nuclear protein from BEAS-2B cells were able to bind to c-Ets-1 promoter 
fragment oligonucleotides containing the Sp1 binding motif from the CYGB promoter 
region. Therefore it is feasible that nuclear localisation of CYGB could be observed. 
  
1.1.6 Putative functions of CYGB 
 
Many functions for CYGB have been suggested; however, its specific role within a cell 
and its function in healthy and damaged tissues is still to be determined, and no 
definitive function for CYGB has been established. The following sections outline the 
current hypotheses about the possible functions of CYGB. 
 
1.1.6.1CYGB and O2 
 
It is generally assumed that intracellular globins, including CYGB, have an important 
role in oxygen homeostasis in mammalian cells. Therefore it was naturally assumed 
that CYGB might be involved in intracellular oxygen storage and transport, or have an 
oxygen sensing role. de Sanctis et al.(2004) proposed that, although CYGB differs in 
structure and tissue distribution from MB and HB, its function is likely to occupy a 
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similar niche as it belongs to the globin superfamily, and the two best studied human 
globins; HB  and MB are involved in oxygen storage and transport (Ascenzi et al., 
2004).The equilibrium constants for O2 and CO in Mb and CYGB are similar, which is 
suggestive of CYGB having a function as an O2 reservoir, as Mb does in muscle tissue. 
However, localisation of CYGB is in cells that form connective and supportive tissue 
from a common ontogenetic origin, and these cells are not usually associated with high 
metabolic rates or high oxygen consumption. Also cellular expression levels cannot be 
reconciled with mitochondria and general metabolic activity, making it unlikely that 
CYGB is directly involved in respiratory chain O2 supply, unlike MB, which shows 
relatively high expression in muscle tissues (Schmidt et al., 2004).CYGB may have a role 
in supplying oxygen for cellular reactions unrelated to mitochondrial respiration (Fago 
et al., 2004), but it has also been reported that dissociation rates of oxygen for hxHbs 
are considered too slow for them to play a role in O2 transport (Smagghe et al., 2008).  
Makino et al. (2011) proposed that if CYGB is a gas sensor, the conformational changes 
that occur to the structure might be a signal, encoding information regarding the O2 
tension and modulate downstream regulators. They also suggest that the crystal 
structure of the CO bound CYGB has a bend in the E helix on the distil side of the 
haem, this feature means the His side chain on the distil side of the haem is expelled 
from the sixth position and moves out of the haem pocket, which could have 
implications for ligand binding affinity. However, a gas sensing function for CYGB was 
dismissed by Schmidt et al. (2004) as CYGB expression is restricted to fibroblast type 
cells and a few neuronal cell types, and there is no apparent reason for this restriction 
in expression for an oxygen sensing molecule. 
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1.1.6.2 CYGB, reactive oxygen species and reactive nitrogen species 
 
CYGB has been implicated in many possible roles in oxygen dependant metabolism 
such as decomposition of reactive oxygen species (ROS) or reactive nitrogen species 
(RNS), or as part of an O2 mediated signalling pathway (Burmester et al., 2007). It has 
been suggested that some functions involving O2 metabolism, specific to fibroblast 
type cells, for example collagen synthesis or perhaps scavenging ROS (Li et al., 2007, 
Ostojic et al., 2008). In vitro, Cygb overexpressing kidney fibroblasts displayed 
increased ROS scavenging activity, and in vivo Cygb overexpressing transgenic rats 
showed decreased oxidative stress (Mimura et al., 2010). Further evidence for a 
protective role was reported by Xu et al.(2006), where primary rat HSCs, transduced 
with rat Cygb were exposed to oxidative stress. Cygb expression reduced production of 
malondialdehyde (MDA) and 4-hydroxy-2-nonenal (4-HNE) lipid peroxidation products 
and total oxyradical scavenging capacity was increased. HSC differentiation into 
myofibroblast type cells induced by oxidative stress was also prevented by 
overexpression of Cygb. Hepatic necrosis induced by CCl4 or bile duct ligation (BDL) 
induced liver fibrosis were inhibited by Cygb overexpression. The fibrogenic phenotype 
development was prevented by Cygb overexpression in CCl4 treated rats, reducing the 
expression of procollagen 1, TGF-β1 and α-SMA. Cygb over expression in BDL rats 
prevented the formation of ascites and inhibited breakdown of liver architecture. 
These data suggest that in vivo up regulation of Cygb doesn’t contribute to HSC-
induced fibrosis but is a homeostatic mechanism for preventing free radical activation 
of HSC and subsequent fibrosis. Reeder et al. (2010) observed pro-oxidant activity of 
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CYGB, which contradicts the reports of CYGB protection against oxidative stress and 
ROS; however, they suggest that at physiological concentrations, and because the 
haem degrades when Fe undergoes redox reactions in the presence of oxygen 
producing ROS (Nagababu and Rifkind, 2004), it would be unlikely that extensive 
cellular damage would be caused, and therefore CYGB might form part of a cell 
signalling cascade inducing an antioxidant response. Fujita et al. (2014) observed 
increased intracellular ROS levels in a melanocyte cell line when CYGB is knocked 
down, as did Singh et al.(2014) in a myoblast cell line, and depletion of CYGB also 
resulted in an increase in cell death in myoblasts. A cytoprotective role for CYGB has 
been proposed; Hodges et al. (2008) reported that cytoprotection from oxidative DNA 
damage was afforded by CYGB against oxidative DNA damage by a singlet oxygen 
generator in a neuron-derived human medulloblastoma cell line, and McRonald et al. 
(2012) found that overexpression of CYGB in the oesophageal cancer cell line TE-8 was 
protective against oxidative stress induced by buthionine sulfoxamine, It is possible 
that CYGB is also involved in NO detoxification, neuronal cells that are positive for 
CYGB also express neuronal NO synthase which produces NO, therefore it is 
conceivable that CYGB is involved in either the production (Hankeln et al., 2005) or 
detoxification of NO (Halligan et al., 2009) or potentially both (Burmester and Hankeln, 
2014). There is evidence that hxHbs bind reversibly to NO (Herold et al., 2004) and in 
the ferric form they react with NO and the oxyferric hxHbs can oxidise NO to nitrate 
and that as a hxHb it could act as an NO dioxygenase Smagghe (2008). Further 
evidence for NO dioxygenase activity was obtained by Gardner et al. (2010) who 
observed reductant activity for ascorbate and cytochrome b(5) and defined an NO 
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dioxygenase function for CYGB in hepatocytes.Halligan et al. (2009) observed Cygb 
expression in adventitial fibroblasts and vascular smooth muscle cells and that 
silencing of Cygb by short hairpin RNA in murine fibroblasts resulted in decreased NO 
consumption and intracellular nitrate production. However it has also been argued 
that due to the low concentrations of hxHbs (including CYGB) in vivo, function as an NO 
scavenger is unlikely (Kakar et al., 2010). Smagghe et al. (2008) report that human 
CYGB shows no ability to catalyse NO destruction and NO binding to ferric human 
CYGB is slower than MB, probably due to intramolecular His binding to the ligand 
binding site, and that it was less efficient as an NO dioxygenase than MB, further 
suggesting that a role in NO detoxification is unlikely.  
 
1.1.6.3 CYGB in hypoxia 
 
CYGB is upregulated in vitro and in vivo under hypoxia (Fordel et al., 2004, Schmidt et 
al., 2004) and CYGB upregulation was found to increase as a function of time under 
hypoxic conditions. Induction of CYGB has been observed in a range of tissues 
including tissues of heart and liver in the fibroblasts and also in the HN33 cell line 
(Fordel et al., 2004). Induction was found to reach maximal levels at 48hr of hypoxia in 
the liver (Fordel et al., 2007). Schmidt et al. (2004) also reported upregulation of Cygb 
mRNA in the heart and liver under hypoxic conditions, with a fold increase of 2.2 + 0.8 
and 2.3 + 0.5 after 22hr and 44hr respectively in the liver. The hypoxia-inducibility and 
hypoxia response of Cygb demonstrates that it probably has a link with oxygen 
dependant metabolism in fibroblasts and fibroblast type cells. Emara et al. (2010), 
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found that in vivo exposure of mice to hypoxic conditions caused significant 
upregulation of CYGB mRNA in human tumours.  
Hamdane et al. (2003) and Lechauve et al. (2010) report that the positions of the 
cysteine residues of CYGB might influence the position of the E helix which could affect 
the affinity of the distil histidine for the haem iron, as is discussed in section 1.1.2. The 
authors suggest that oxidative stress might cause a change in the local redox state in 
response to physiological stimuli and cause formation or breaking of an intramolecular 
B2-E9 disulphide bond, leading to a conformational change which affects oxygen 
affinity. They propose that, as hypoxia results in the accumulation of reducing agents 
in the cell, which have the ability to reduce the disulphide bond, CYGB may play a role 
in countering hypoxia by releasing oxygen via the conformational change induced 
under the reducing conditions caused by hypoxia. When oxygen concentration 
increases, the cysteines will be oxidised into the intramolecular disulphide bonds and 
oxygen affinity increased leading to oxygen storage, and this could be a signalling 
response, rather than O2 storage per se. However this response does not explain why 
CYGB expression seems to be restricted to cells of a fibroblast lineage, but it could be 
involved in a signalling pathway specific to this cell type. 
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1.1.6.4 Enzymatic activity of CYGB 
 
It has been postulated that Cygb might have an enzymatic function as a peroxidase 
Kawada et al. (2001) found, on analysis of purified ‘STAP’, that it exhibited peroxidase 
activity and suggested a role for Cygb in facilitating oxygen diffusion to the respiratory 
chain of the mitochondria, along with Burmester et al. (2002). Peroxidase activity was 
also observed by Reeder et al. (2011), who suggested that disruption of 
hexacoordination along with the ability of CYGB to induce lipid oxidation in vitro may 
be an explanation for this activity, and could be important in the physiological role of 
CYGB. Schmidt et al. (2004) argue that a function as a terminal oxidase in anaerobic 
conditions is unlikely, and the strong pseudo-peroxidase exhibited by Cygb activity 
could be explained by its interaction with lipids, its ability to induce lipid oxidation 
reactions in in vitro experiments and the reported lipid-binding properties of Cygb. 
Authors have argued that this activity could have an important role in the physiological 
function of the Cygb protein (Schmidt et al., 2004, Reeder et al., 2011, Ascenzi et al., 
2013). 
 
1.1.7 CYGB and collagen I synthesis 
 
Schmidt et al. (2004) proposed that Cygb may supply oxygen to prolyl-4-hydroxylase 
for the hydroxylation of proline residues in the procollagen molecule (Pihlajaniemi et 
al., 1991, Myllyharju and Kivirikko, 1999), as the degree of collagen hydroxylation 
depends on available oxygen (Yen et al., 1979). This hypothesis is consistent with the 
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observation that Cygb is upregulated in fibrotic livers, where collagen synthesis is also 
increased (Kawada et al., 2001). Collagen mRNA is also upregulated in hypoxic 
conditions in vitro and in vivo (Takahashi et al., 2000, Genin et al., 2008). Schmidt et 
al.(2004) found that Cygb is upregulated in hypoxic conditions, and hypothesise that 
Cygb compensates for low oxygen conditions and increased oxygen demand for 
collagen synthesis. Man et al. (2008) also indicate a link between Cygb upregulation 
and collagen synthesis. After in vivo treatment of mice with CCl4, collagen staining was 
only observed after 48hrs. Cygb staining was stronger at 6hr increasing to 24hr and 
then decreased again at 48hr. Collagen mRNA expression was down regulated up to 
24hr and then significantly upregulated at 48hr, suggesting Cygb could be involved in 
collagen synthesis. Also over 8 weeks of induced liver fibrosis the number of cells 
positive for Cygb in the fibrotic septa increased. However, in vitro primary cultured 
fibroblasts from transgenic rats showed Cygb overexpression at mRNA and protein 
levels but reduced collagen production. Also, mutant Cygb with an altered haem group 
to impair ligand binding showed no effect of reduced collagen production (Mimura et 
al., 2010), evidence against a role for Cygb as an O2 donor in collagen synthesis. These 
results, however, are only correlative, and no firm mechanistic link between Cygb and 
collagen synthesis has been established. 
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1.1.8 CYGB in disease 
 
CYGB has been implicated in many disease states, it was first discovered on analysis of 
protein changes in a model of liver fibrosis as discussed in section 1.1 (Kawada et al., 
2001), it is also upregulated in kidney fibrosis (Mimura et al., 2010) and some 
neurodegenerative disorders (Hedley-Whyte et al., 2009). In the liver, loss of Cygb 
leads to increased chemically-induced tumorigenesis (Thuy le et al., 2011) and it 
appears to have a role in cancer, with many cancers showing CpG site methylation of 
the CYGB promoter region (Xinarianos et al., 2006, Shivapurkar et al., 2008, 
Wojnarowicz et al., 2012, Shaw et al., 2013, Fujita et al., 2014), leading to reports of it 
acting as a tumour suppressor (Shivapurkar et al., 2008). However, upregulation has 
also been reported in some cancers, such as head and neck and alveolar soft-part 
sarcoma (Genin et al., 2008, Shaw et al., 2009). Cygb is upregulated in hypoxic 
conditions (Fordel et al., 2004, Schmidt et al., 2004) and solid tumours often have 
hypoxic regions and tumour hypoxia is associated with tumour progression (Hockel et 
al., 1996, Hockel and Vaupel, 2001). These observations have led to the suggestion 
that CYGB can also act as on oncogene (Oleksiewicz et al., 2013). 
 
1.1.8.1 CYGB in cancer 
 
CYGB was first associated genetically with cancer by McRonald et al. (2006) in tylosis 
with oesophageal cancer (TOC), which is an autosomal dominant hereditary disorder 
associated with higher risk of oesophageal cancer and oral lesions (Risk et al., 1999). 
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The CpG site of CYGB can be methylated, and gene silencing of CYGB by methylation 
has been reported in many cancers including: non-small cell lung cancer (Xinarianos et 
al., 2006), lung, colon, bladder and breast cancer and leukaemia, (Shivapurkar et al., 
2008), head and neck cancer (Shaw et al., 2009), the recurrence of hepatocellular 
carcinoma (Yang et al., 2011), ovarian cancer (Wojnarowicz et al., 2012) oral squamous 
cell carcinoma (Shaw et al., 2013) and melanoma cells (Fujita et al., 2014). CYGB 
promoter methylation has proved to be useful in distinguishing cancerous from normal 
tissue (Shivapurkar et al., 2008), suggesting that it might be useful as epigenetic 
biomarker for cancer detection (Shaw et al., 2007). It is known that promoter 
hypermethylation that is related to cancer frequently affects expression of tumour 
suppressor genes the expression of tumour suppressor genes (Esteller, 2007), and it 
has been postulated that CYGB acts as a tumour suppressor (Shivapurkar et al., 2008, 
Oleksiewicz et al., 2013). It has been shown that increased expression of CYGB reduced 
colony formation in lung and breast cancer cell lines (Shivapurkar et al., 2008), cell 
migration, invasion and anchorage in lung cancer cell lines (Oleksiewicz et al., 2013) 
and proliferation in ovarian cancer cell lines (Chen et al., 2014), conversely, CYGB 
silencing via siRNA in melanoma cells increased cell proliferation (Fujita et al., 2014). 
Thuyet al. (2011) demonstrated increased tumorigenesis in the livers of Cygb deficient 
mice treated with DEN (N,N-diethylnitrosamine) 
However, it also appears that CYGB can have tumour promoter properties as well, it is 
upregulated in head and neck cancer, lung carcinoma and alveolar soft-part sarcoma 
(Xinarianos et al., 2006, Genin et al., 2008, Shaw et al., 2009, Oleksiewicz et al., 2013). 
Hypoxia response seems to be a component of upregulation in these cancers. In 
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hypoxic conditions Cygb is upregulated (Fordel et al., 2004, Schmidt et al., 2004) and 
tumour hypoxia is associated with tumour progression and resistance to radiotherapy 
and chemotherapy (Hockel et al., 1996, Hockel and Vaupel, 2001). It is thought that 
CYGB might offer cytoprotection under stress conditions such as hypoxia (see section 
1.1.6.3), which might be the mechanism for CYGB’s tumour promoter properties. 
Oleksiewicz et al. (2013) recently demonstrated CYGB conferred protection on lung 
cancer cell lines, in a cell specific manner, under hypoxic conditions.  
 
1.1.8.2 CYGB in fibrosis 
 
Fibrosis is a common complication of the chemotherapy and radiation treatments that 
are used for the treatment of cancer (Mancini and Sonis, 2014), as well as being 
apparent in other types of disease such as kidney and liver disease. It has also been 
argued that the formation of a fibrotic extracellular matrix stimulates cells to 
proliferate, creating conditions for cancer development (Cernaro et al., 2012). A role 
for CYGB in the process of fibrosis has been suggested because several studies shown 
it be upregulated during fibrogenesis along with collagen expression (Kristensen et al., 
2000, Nakatani et al., 2004, Schmidt et al., 2004 , Mimura et al., 2010, He et al., 2011). 
Cygb has been reported to be induced in in vivo in a fibrotic liver, and in vitro in 
activated HSCs implying it has an active role in the process of fibrosis as HSC are the 
major ECM producing cells in an injured liver, there contribute greatly to fibrogenesis 
in this organ (Kristensen et al., 2000) (section 1.2.1.2). Schmidt et al. (2004) observed 
strong Cygb expression in HSCs, and also in the fibroblasts forming connective tissue of 
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blood vessels, and fibroblasts in many other tissues, but not in hepatocytes. Hydrogen 
peroxide, which induces a fibrotic response in cells, induced CYGB upregulation in N2a 
neuroblastoma cells (Li et al., 2007) and upregulation of CYGB has not been observed 
with other forms of stress such as heat stress, high osmolarity and UV radiation 
(Reeder et al., 2011). Mimura et al. (2010) found that Cygb is upregulated in an in vivo 
model of the fibrotic kidney in a time dependant manner in both mRNA and protein 
expression, along with collagen and HIF expression. Initial data indicated that Cygb 
could be profibrotic; however more recent research has suggested an antifibrotic 
effect of increased Cygb expression. He et al. (2011) demonstrated that treatment with 
Cygb reduced collagen deposition and fibrotic marker expression in thioacetamide 
induced fibrosis in rats in vivo, and reduced cell viability, in a concentration dependent 
manner, in HSC cell lines in vitro. Cui et al. (2012) observed that arundic acid inhibited 
HSC activation via an increase in CYGB expression in a human HSC cell line and primary 
rat HSCs. Cygb deficient mice develop more fibrosis after ischemia-reperfusion (IR) 
injury in the heart (Singh et al., 2013) and inhibition of pancreatic stellate cell 
activation by halofuginone reduces pancreas fibrosis and was accompanied by an 
increase in Cygb in these cells (Zion et al., 2009). 
There are as yet no definitive answers to the question of the role of CYGB within 
healthy or diseased tissue, or in cells. However, many aspects of CYGB indicate a role 
within the processes of disease and fibrosis. 
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1.2 Hepatic Stellate Cells  
 
Cygb was first identified in an in vivo proteomic study of liver fibrosis in rats treated 
with CCl4. It was reported as an unidentified protein upregulated in HSC upon their 
activation, and named STAP (Kristensen et al., 2000), as described in section 1.1. HSC 
are key players in the process of liver fibrosis and are the major source of the ECM 
which forms the hepatic scar in a fibrotic liver (outlined in more detail in section 
1.2.1.2). CYGB has been implicated in fibrosis (see section 1.1.8.2) and therefore its 
regulation in hepatic cells might be important in the activation state of these cells and 
their role in liver fibrosis.  
HSCs were first described as ‘sternzellen’ (German for ‘star cells’) by Kupffer in 1876, 
who visualised them using gold chloride to detect Vitamin A containing droplets 
(Wake, 1971). An important functional role for stellate cells in the injury response of 
the liver was described by Kent et al. (1976) Okanoue et al.(1983) and Yokoi et 
al.(1984), who observed that HSCs were found in close proximity to collagen fibres in a 
fibrotic liver. This work also suggested that HSCs might be the antecedent of the 
fibroblasts frequently described in liver injury. There was also evidence for regular 
association between HSC and ECM (Martinez-Hernandez, 1984). 
It became evident that the multitude of names used to describe HSCs, such as Ito cells, 
lipocytes, parasinusoidal or perisinusoidal cells and fat storing cells, was causing 
confusion in the scientific field (Friedman, 2008b), so in 1996 the international 
community of researchers in the field of nonparenchymal liver cell biology and liver 
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fibrosis made the recommendation that they should be referred to as 'hepatic stellate 
cells' in all publications from January 1997 onwards. 
 
1.2.1 HSC function 
 
It is widely accepted that HSCs are the principle effectors of hepatic fibrogenesis and 
have become recognised as versatile mesenchymal cells, which are vital for 
hepatocellular function, and the liver’s response to injury (Friedman, 2008b). On liver 
injury HSC transform from quiescent vitamin A storing cells to activated myofibroblast 
type cells. However, they are not the sole effectors as other mesenchymal cells, such 
as hepatocytes, cholangiocytes, and portal fibroblasts also secrete ECM, and so 
contribute to the formation of the hepatic scar (Friedman, 2008a). HSC activation, 
however, is the dominant profibrotic pathway (Friedman, 2008c) in liver fibrosis and it 
has been suggested that HSCs are only one source of myofibroblast like cell, which 
deposit ECM during liver fibrosis (Kinnman et al., 2003, Beaussier et al., 2007). In a fate 
tracing experiment, Mederacke et al. (2013) found that HSCs became 82-96% of 
myofibroblasts in in vivo mice models of toxic, cholestatic and fatty liver disease, it is 
therefore obvious that HSCs are important in the fibrotic process in the liver. 
 
1.2.1.1 HSCs in a normal liver 
 
HSCs are located between the basolateral surface of hepatocytes and the anti-luminal 
side of the sinusoidal endothelial cells in the subendothelial space (Space of Disse) 
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(Figure 1.4). They account for approximately one third of the nonparenchymal cells of 
the liver and 15% of the total liver cell population of a normal liver (Giampieri et al., 
1981, Jezequel et al., 1984). In an uninjured liver HSC are quiescent, and a major 
characteristic of quiescent HSCs is the presence of intracellular retinoids in the form of 
cytoplasmic lipid droplets, this constitutes 70-80% of total liver - and therefore whole 
body - retinol content. These retinoids are released on HSC activation, and there is a 
marked depletion in retinoic acid (RA) content of activated HSC (Senoo, 2004, She et 
al., 2005, Krizhanovsky et al., 2008, Kisseleva et al., 2012). 
 
1.2.1.2 Function on liver injury 
 
Activation of HSCs upon liver injury, by any means, occurs in two major phases: 
initiation and perpetuation. Initiation is mainly induced by paracrine stimulation whilst 
the perpetuation phase involves autocrine as well as paracrine loops. During activation 
HSC become highly proliferative and excrete ECM rich in collagen type I (Reeves and 
Friedman, 2002). 
Initiation is characterised by early stage changes in gene expression and phenotype, 
making cells responsive to cytokines and other stimuli (Reeves and Friedman, 2002), 
initiation is also known as the ‘preinflammatory stage’. These first stages of changes to 
HSCs are primarily caused by paracrine stimulation by all adjacent cell types including 
hepatocytes, sinusoidal epithelial cells, Kupffer cells and platelets, which together 
result in the production of fibronectin, transforming growth factor beta( TGF-β)`, 
32 
 
platelet derived growth factor (PDGF) and epidermal growth factor (EGF). Damaged 
hepatocytes are also an important source of lipid peroxides and apoptotsis of 
hepatocytes has been shown to be profibrogenic to HSC in culture (Canbay et al., 2002, 
Friedman, 2008a). Also implicated in the initiation phase of HSC activation is 
cytochrome P450 2E1 (CYP2E1), which was shown to have an important role in the 
production of ROS such as H2O2 when the rat HSC-T6 cell line was co-cultured with the 
hepatocyte cell line Hep-G2, which in turn stimulate HSCs (Nieto et al., 2002). As 
discussed in section 1.1.6.2 CYGB has been implicated in ROS regulation, potentially 
having a protective role, or it might be involved in ROS mediated signalling to initiate 
processes specific to fibroblast type cells such as collagen synthesis (Li et al., 2007, 
Ostojic et al., 2008). HSCs are stimulated by ROS and also deposit collagen upon 
activation, therefore the presence of CYGB in these cells suggests a role in redox 
regulation or signalling in HSCs. Recent research has indicated that CYGB has an 
antifibrotic role as discussed in section 1.1.8.2. 
Perpetuation refers to the effect of these paracrine stimuli on HSCs, where the 
activated phenotype is maintained, sustaining the fibrogenic process. Perpetuation is 
dependent on a number of functional changes such as stellate cell proliferation and 
chemotaxis, matrix degradation, fibrogenesis, increased cell contractility, inflammatory 
cell infiltration and loss of retinoids (Reeves and Friedman, 2002, Friedman, 2008b). In 
total, six separate changes in cell behaviour are required for perpetuation of HSC 
activation (Friedman, 2008b). Firstly proliferation is provoked, PDGF has been 
implicated as the main protagonist in the process of proliferation (Pinzani, 2002, 
Borkham-Kamphorst et al., 2008). PDGF is also involved in the chemotaxis of stellate 
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cells towards cytokine chemoattractants (Ikeda et al., 1999, Kinnman et al., 2000). 
Fibrosis is due to increased HSC numbers and increased matrix production, 
predominantly collagen 1α1 (Friedman, 2008a).The most potent stimulus for fibrosis is 
the cytokine TGF-β, from both paracrine and autocrine sources (Gressner et al., 2002, 
Breitkopf et al., 2006, Inagaki and Okazaki, 2007). Increased amounts of α- smooth 
muscle actin (αSMA) are expressed in activated cells, and this is used as a marker of 
HSC activation (Reynaert et al., 2002).  
 
1.2.1.3 Senescence of HSCs 
 
It is known that removal of the injury inducing insult to the liver, be it infection or drug 
toxicity, results in apoptosis and senescence of HSC and their clearance by natural 
killer cells (Weiner et al., 1992, Ohata et al., 1997, Iredale et al., 1998, Krizhanovsky et 
al., 2008), and a corresponding decrease in fibrosis is observed, discussed in section 
1.2.4. Recent research has reported that HSCs can also return to an inactive 
phenotype, rather than just apoptosing and being cleared. Hazra et al., (2004), 
demonstrated that forced expression of peroxisome proliferator-activated receptor γ 
(PPAR-γ) confers a quiescent phenotype on culture activated primary rat HSCs, as 
observed by cell morphology, proliferation and DNA synthesis, activation marker gene 
expression, such as α1 procollagen, TGF-β1, αSMA and collagen I and also retinyl ester 
accumulation. Kisseleva et al., (2012) reported that not all HSCs are cleared from a 
regressed liver, some return to an inactivated state, which is similar to, but distinct 
from quiescent HSCs in terms of gene expression and a more ready response to 
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fibrogenic stimuli, they termed these inactivated HSCs (iHSCs). Figure 1.5 is a 
schematic of the activation of HSC through initiation, perpetuation and resolution. 
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Figure 1.4: Changes in the sinusoid and Space of Disse on liver injury and development of fibrosis. Apoptosis of 
hepatocytes and activation of Kupffer cells contributes to activation of Hepatic Stellate Cells, leading to loss of 
hepatocyte microvilli and deposition of ECM scar proteins. 
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Figure 1.5: The process of HSC activation through initiation, perpetuation and possible resolution. 
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1.2.1.4 Transcription factors involved in the regulation of HSC activation and 
quiescence in the context of CYGB regulatory elements 
 
The transformation of quiescent HSC to activated HSC and vice versa requires many 
changes in gene expression, and regulation of gene transcription is, therefore, 
important in the conversion and maintenance of an activated HSC phenotype in an 
injured liver (Mann and Mann, 2009). Cygb is reported to be upregulated in activated 
HSC compared with quiescent HSC (Kristensen et al., 2000), indicating transcriptional 
regulation of CYGB in the transformation of HSC from a quiescent to an activated. 
Regulation of CYGB expression is discussed in section 1.1.4.1, and there is overlap 
between transcription factor binding sites present in the CYGB promoter region and 
transcription factors that are important in HSC modulation, Figure 1.6 depicts this 
overlap. HSCs express α, β and δ C/EBPs (Huang et al., 2004), and CYGB contains a 
C/EBP binding site within its promoter. Huang et al. (2009), discovered that C/EBPα 
(which controls differentiation in adipocytes) is downregulated in activated HSCs and 
forced overexpression inhibited proliferation, ECM producing gene expression and 
induced lipid droplet storage in HSC suggesting a more quiescent phenotype, indicating 
a role for C/EBPα in HSC differentiation. Krupple-like zinc finger proteins are also 
expressed in HSC, most significant with regards to CYGB is SP1, which is induced on 
HSC activation, and its DNA binding activity increased. SP1 has been shown to induce 
collagen 1α gene transcription in activated HSCs; however interactions with NFκB 
reduced SP1’s transcriptional activity (Mann and Mann, 2009). Increased expression of 
SP1 in activated HSC may impact CYGB gene transcription in these cells. AP-1 factors 
such as c-Jun, JunB, Jun D, and c-Fos, Fra1 (Fos-related antigen 1), Fra2, and Fos-B (FBJ 
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murine osteosarcoma viral oncogene homolog B) are regulators of tissue inhibitors of 
metalloproteinase (TIMP) -1 expression, which is involved in inhibiting ECM 
degradation – an important event in fibrosis. In quiescent HSCs, DNA binding of AP-1 is 
not detectable, but is induced during the early stages of HSC activation (Knittel et al., 
1999, Friedman, 2008b, Mann and Mann, 2009), where it could influence CYGB gene 
transcription. Another transcription factor involved in HSC regulation which might have 
a role in CYGB transcription is AP-2, which also regulates collagen 1 promoter activity 
in HSCs (Chen et al., 1996). Binding of the transcription factor NF-1 can also regulate 
collagen gene transcription in activated HSCs (Anania et al., 1995). Quiescent and 
activated HSCs both express Ets1 (E26 transformation-specific transcription factor), but 
it is more highly expressed quiescent HSCs, as HSC activate, the transcription, protein 
and binding activity of Ets1 are greatly reduced (Knittel et al., 1999). The CYGB 
promoter contains a c-Ets-1 binding motif, so the expression pattern of ETs1 in HSCs 
could influence CYGB expression in this cell type. NFκB is also expressed in both 
quiescent and activated HSC, and transcriptionally active NFκB is increased in activated 
HSC, this activation seems to be a permanent reprogramming, and an increase in basal 
activity levels to perpetuate pro-inflammatory and pro-fibrogenic gene expression and 
prevent apoptosis of HSC (Elsharkawy et al., 2005, Tergaonkar, 2006). Antioxidants 
have been shown to have an inhibitory effect on NFκB (Chen et al., 1996), and CYGB 
has been shown to have antioxidant activity (see section 1.1.6.2), so feedback could be 
occurring through NFκB binding to the CYGB promoter. 
 
39 
 
To date no studies have specifically looked at the binding of transcription factors that 
are involved in HSC differentiation to the CYGB promoter region in these cells, so it is 
not yet known if the overlap between transcription factors expressed by HSC and CYGB 
regulatory elements is of significance in these cells. Transcriptional regulation of HSC is 
complex, and many transcription factors interact, making understanding these 
processes difficult. However it is clear that HSC differentiation and CYGB expression 
correlate. Motoyama et al. (2014) have since reported that Cygb expression is specific 
HSCs, whether they are quiescent or activated, in normal and fibrotic livers and is 
present in primary mouse HSC throughout 7 days of culture. Thus Cygb could be used 
to distinguish myofibroblasts originating from HSCs from those derived from other cell 
types. It is also possible that CYGB could be a target for manipulating HSC 
transformation, the crossover between many transcription factors involved in HSC 
activation and CYGB genetic regulation are indicative of a role in this process for CYGB. 
Mann and Mann (2009), expressed the view that unravelling the signalling processes 
involved in HSC regulation could lead to therapeutic targets for prevention and 
reversion of liver fibrosis. 
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Figure 1.6: Transcription factors important in hepatic stellate cell (HSC) activation that are also important in the 
context of regulatory elements present in the promoter region of cytoglobin (CYGB). Abbreviations: C/EBP = 
CCAAT-enhancer-binding protein, Ets1 = E26 transformation-specific transcription factor, cEts-1 = cellular 
erythroblastosis virus E26 oncogene homolog 1, NFκB = nuclear factor kappa-light-chain-enhancer of activated B 
cells, AP = activator protein, SP = stimulatory protein. Crystal protein structure of homodiamer of Cygb modified 
from http://www.rcsb.org/pdb access number 1UMO (de Sanctis et al., 2004) 
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1.2.2 Liver fibrosis 
 
Liver fibrosis is caused by chronic damage to the liver and is characterised by the 
accumulation of ECM (Friedman, 2003). Acute liver injury causes regeneration and 
replacement of necrotic and apoptotic cells by parenchymal cells in association with an 
inflammatory response with limited ECM deposition. However if the injury is chronic 
then the regenerative response fails and scar tissue containing fibrillar collagen forms 
in the place of hepatocytes. If liver injury is continuous, or the liver is repeatedly 
assaulted, then the wound healing response in the liver results in fibrosis, the 
increased ECM consists mainly of collagen and creates a hepatic scar (Reeves and 
Friedman, 2002). Advancing of liver disease causes bridging fibrosis, and then cirrhosis 
occurs. The onset of liver fibrosis normally goes clinically undetected as morbidity and 
mortality only occur after cirrhosis develops (Poynard et al., 2003). The progression of 
fibrosis to cirrhosis can take 15—20 years, and can include complications such as renal 
failure, hepatic encephalopathy and hepatocellular carcinoma. In compensated 
cirrhosis, patients can survive complication free for several years; however 
decompensated cirrhosis is associated with short survival. It is possible that in some 
circumstances fibrosis can proceed rapidly to cirrhosis, including acute alcoholic 
hepatitis (Bataller and Brenner, 2005).  
Fibrosis occurs due to a series of events; inflammation usually precedes fibrosis and 
involves the recruitment of inflammatory cells to the site of injury, which is a normal 
part of wound healing. Then chronic injury occurs, which involves immediate damage 
to the barrier between the epithelial and endothelial cells and release of TGF-β1. This 
42 
 
in turn induces ROS production, and myofibroblast type cells, which deposit collagen, 
are activated, these include HSCs, which lose their retinoids and activate in the manner 
described in section 1.2.1.2. If the injury is removed then fibrosis is reversed, however 
if it is continuous then fibrosis can develop into cirrhosis (Wallace et al., 2008). Fibrosis 
is defined as detectable deposits of ECM. In a non-fibrotic liver, ECM constitutes 
approximately 3% of the relative area of a liver section, where as in a cirrhotic liver, 
approximately 22% the area of liver section is covered (Lin et al., 1998). As the major 
contributors to ECM deposition on liver injury, activated HSCs are very important in 
the progression of fibrosis in the liver. Figure 1.4 illustrates the changes which occur to 
the liver on injury. 
There is increasing evidence that a regression of fibrosis in the liver is possible, despite 
the impression clinically that it is not , discussed in section 1.2.4 (Davis et al., 1990, 
Troen et al., 1994, Sato et al., 1995, Benyon and Iredale, 2000, Ramachandran and 
Iredale, 2012).  
 
1.2.3 Changes in ECM 
 
The amount and composition of ECM is altered during fibrosis (Benyon and Iredale, 
2000). In advanced liver fibrosis there can be six times more ECM than found in a non-
fibrotic liver. The composition changes from one dominated by collagen IV and laminin 
(Martinez-Hernandez and Amenta, 1995), to one of fibrillar collagen, predominantly 
collagen I and III with a corresponding increase in fibronectin and elastin amongst 
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other components (Friedman, 2008c). ECM accumulation is caused by an increase in 
synthesis and a decrease in degradation (Arthur, 2000). The imbalance between matrix 
production and degradation is critical in liver fibrosis, and early degradation of normal 
matrix causes replacement with scar matrix (Friedman, 2008c). The ECM provides 
several functions within the liver, it is a mechanical scaffold for cellular adhesion, 
migration and interactions, and it acts as a reservoir for paracrine soluble factors such 
as PDGF and TGF-β, as well as other stimuli involved in activation and matrix 
modulation (Reeves and Friedman, 2002). Changes in ECM composition also drive 
changes in membrane receptors, particularly integrins, indicating the ECMs’ role not 
only as a scaffold but as part of the cell-cell communication network via cell-surface 
receptors (Benyon and Iredale, 2000, Bedossa and Paradis, 2003, Friedman, 2008c). 
The primary source of ECM in the liver are activated HSCs (Gabele et al., 2003), 
outlined in section 1.2.2. Activated HSCs deposit collagens type I and III into the ECM 
(Friedman, 2008b) and the initiation of HSC activation takes place alongside the 
progressive changes in the surrounding ECM.  
 
1.2.4 The reversibility of liver fibrosis 
 
Liver fibrosis has traditionally been thought of as an irreversible process; however this 
view is changing, Pellicono et al. (2012) described the belief that fibrosis is 
unidirectional as obsolete. It has been shown that abstinence from alcohol can 
improve lesions in the liver in patients with alcoholic liver disease (Pares et al., 1986) 
and pegylated interferon and ribavirin combination therapy for hepatitis C reversed 
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cirrhosis in 49% of patients (Poynard et al., 2002). Experimental models have shown 
feasibility of reversing liver fibrosis in vivo, Iredale et al. (1998) showed that 
spontaneous recovery from CCl4 induced liver fibrosis occurred over a 28wk period in 
rats. A similar result was observed by Issa et al. (2004), in CCl4 induced liver cirrhosis in 
a rat model. Tissue inhibitor of metalloproteinase-1 (TIMP-1) seems to have an 
important role in preventing fibrosis resolution in the liver, it has an antiapoptotic 
effect on HSCs and activated HSCs are a source of TIMP-1, when a liver spontaneously 
recovers from fibrosis there is a corresponding decrease in TIMP-1 expression (Murphy 
et al., 2002). It has been observed that during spontaneous resolution of liver fibrosis 
apoptosis of HSC occurs and they are cleared by natural killer cells (Weiner et al., 1992, 
Ohata et al., 1997, Iredale et al., 1998, Krizhanovsky et al., 2008). Recent research has 
also shown that HSCs can senesce as discussed in section 1.2.1.3, stopping their 
profibrogenic activity and returning to a quiescent state, which could also be an 
important factor in the reversal of liver fibrosis.  
 
1.3 Liver disease 
 
Activated HSCs are the major contributors to the hepatic scar, which, if it progresses, 
leads to cirrhosis. All chronic liver diseases can lead to fibrosis and eventually cirrhosis. 
The incidence of liver disease is increasing, and it is therefore important to understand 
the process of HSC activation and discover possible treatment targets like CYGB. 
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1.3.1 Overview of liver disease 
 
Approximately 29 million people in Europe suffer from a chronic liver condition; liver 
cirrhosis is the cause of around 170,000 deaths, and liver cancer 47,000 deaths, per 
annum in Europe. Mortality from liver disease is comparable with other diseases that 
have a high degree of public and media attention, such as breast cancer (Blachier et 
al., 2013). Effiong et al., (2012) reported that deaths from liver disease in England are 
increasing. Between 2001 and 2009 there was a rise of 25% in deaths from liver 
disease, and liver disease now accounts for approximately 2% of deaths in England, 
this statistic contrasts with many other causes death due to disease which are in 
decline. Liver fibrosis is apparent in all chronic liver diseases, and fibrogenesis is the 
physiological response of the liver to insult or injury (Reeves and Friedman, 2002, 
Bedossa and Paradis, 2003), which can result in organ failure if not treated (Rojkind et 
al., 2002). 
 
1.3.2 Types of liver disease 
 
The major causes of liver fibrosis in industrialised countries are HCV infection, 
excessive alcohol consumption and non-alcoholic steatohepatitis (NASH), liver diseases 
such as haemochromatosis and toxins, immune system disorders and parasitic 
infections are also prevalent (Reeves and Friedman, 2002). The development of liver 
fibrosis is determined by genetic as well as environmental factors (Bataller and 
Brenner, 2005). But, despite the different forms injury induction may take, the 
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response of the liver in terms of cellular behaviour and paracrine soluble factor release 
is similar (Reeves and Friedman, 2002). Table 1.1 outlines some of the major 
aetiologies and diseases associated with the development of liver fibrosis. 
As well as the diseases outlined in Table 1.1, liver cancer is a major disease of the liver, 
responsible for around 47,000 deaths in the European Union per year and the 
mortality rate is close to the incidence rate as survival is low (Blachier et al., 2013). 
Primary research into HSC activation has the potential to identify targets for the 
treatment of liver disease. Factors important in the transition of HSCs from quiescent 
to activated could be targeted and manipulated to ameliorate ECM deposition and 
lessen fibrogenesis, or return activated HSCs to a quiescent state, preventing further 
deposition of ECM and assisting the process of fibrosis reversal. It is conceivable that 
CYGB could be one of these targets.  
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Table 1.1: Diseases of the liver 
Disease Pathogenesis Epidemiology   References 
 
Alcoholic Liver 
Disease (ALD) 
 
Not completely 
understood, however 
involves metabolism of 
alcohol through 
cytochrome P450 2E1 
producing reactive 
oxygen species (ROS) 
leading to lipid 
peroxidation, and also 
to acetaldehyde then 
acetate, which in turn 
leads to the production 
of nicotinamide 
adenine dinucleotide 
(NADH) inhibiting fatty 
acid oxidation. 
 
Alcohol is the main cause of 
liver disease in England and 
Europe as a whole. Alcohol 
consumption increased and 
stabilised between 2004 
and 2006 but there is great 
variation between 
countries.  
(Forrest and 
Reed, 2011, 
Effiong et 
al., 2012, 
Blachier et 
al., 2013) 
 
Alcoholic 
Steatohepatitis 
(ASH) 
A subtype of ALD, ASH 
is the consequence of 
alcohol metabolism 
inhibition of fatty acid 
oxidation and lipid 
accumulation in the 
liver. 
 
As with ALD (Stickel and 
Seitz, 2010) 
 
Non-Alcoholic Fatty 
Liver Disease 
(NAFLD) 
Accumulation of fat in 
livers from dietary free 
fatty acids (FFAs) and 
FFA influx, and de novo 
lipogenesis due to 
insulin resistance (IR). 
Defined as the 
presence of steatosis in 
histological samples. 
Considered the 
manifestation of IR in the 
liver 20% to 30% of those 
presenting NAFLD develop 
non-alcoholic 
steatohepatitis. 80-90% of 
NAFLD patients are obese 
adults. It is endemic in 
Europe and causes 0.1% of 
all deaths in England. 
 
(Petta et al., 
2009, 
Bellentani et 
al., 2010, 
Effiong et 
al., 2012, 
Blachier et 
al., 2013) 
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Non-Alcoholic 
Steatohepatitis 
(NASH) 
Pathogenesis of NASH 
is poorly defined. Fatty 
liver consequently 
leads to NASH, and a 
‘two-hit’ model has 
been proposed. The 
first hit involving 
obesity, IR and 
adipokines and 
cytokines, and the 
second hit involving 
oxidative stress, 
apoptosis and 
endotoxins. NASH is 
defined as the presence 
of fatty degeneration of 
a liver biopsy sample 
with inflammation and 
with or without 
fibrosis. 
 
Diagnosis requires a liver 
biopsy so prevalence in the 
general population is 
unknown, and the majority 
of patients are 
asymptomatic. But it is a 
progression from NAFLD. 
(Powell et 
al., 1990, 
Petta et al., 
2009, 
Khedmat 
and Taheri, 
2011) 
 
Viral Hepatitis 
Inflammation of the 
liver due to one of five 
hepatitis viruses; 
hepatitis A (HAV) has 
mainly faecal-oral 
transmission through 
contaminated food and 
water, hepatitis B (HBV) 
transmitted through 
percutaneous and 
mucosal exposure to 
infected body fluids, 
hepatitis C (HCV) is 
transmitted through 
exposure to infected 
blood, hepatitis D 
(HDV) requires the 
presence of HBV to be 
HAV: Global occurrence, 
but regions vary in severity, 
rarely fatal but has a 
substantial economic 
burden. 
 
HBV: One of the world’s 
most widespread infections. 
500,000-700,000 deaths are 
associated with HBV. 
 
HCV: Estimated 150 million 
people have a chronic HCV 
infection and 350,000 
deaths a year are 
associated with HCV. 
 
HDV: Dual infection with 
(Forrest and 
Reed, 2011, 
Chuang et 
al., 2009) 
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infective, hepatitis E 
(HEV) is also faecal-
orally transmitted as 
with HAV. 
All cause liver disease 
but vary in their 
epidemiology, 
prevention and 
diagnosis.  
 
HBV produces worse 
patient outcomes. 
 
HEV: There are an 
estimated 3.4 million 
symptomatic cases, 70,000 
deaths and 3000 still births 
associated with HEV per 
year.  
 
Primary Biliary 
Cirrhosis (PBC) 
An auto-immune 
disease, and there is 
also evidence that 
genetic predisposition 
is a factor in 
development. Precise 
mechanisms are 
unknown, but there is a 
progressive destruction 
of biliary epithelial cells 
and therefore intra-
hepatic bile ducts 
leading to liver cirrhosis 
and liver failure. 
 
There is a predominance of 
PBC in women, but it is a 
rare disease in general. 
Progression is variable. 
(Blachier et 
al., 2013) 
 
Primary Sclerosing 
Cholangitis (PSC) 
Regarded as immune 
mediated, rather than 
auto-immune, PSC has 
an unknown aetiology, 
but it has an 
association with 
inflammatory bowel 
disease (IBD), toxic bile 
composition and 
genetic susceptibility. It 
is asymptomatic and 
differs in its 
manifestation. 
 
PSC is rare, but has a 
greater prevalence in 
Northern and Nordic 
countries. It is predominant 
in young men, aged 
between 30 to 40yrs. 
(Stickel and 
Seitz, 2010, 
Blachier et 
al., 2013) 
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Haemochromatosis 
Haemochromatosis is 
associated with mis-
sense mutations in the 
‘High Iron’ or HFE (Fe 
for iron) gene 
(chromosome 6p21.3) 
which facilitates and 
regulates iron transport 
in hepatocytes, and 
also hepcidin (a 
ferroportin degradation 
hormone) deficiency, 
leading to increased 
iron absorption and 
iron overload. 
Haemochromatosis is rare 
and diagnosis often 
delayed. Gene 
homozygosity is most 
prevalent in north western 
European countries. 
(Khedmat 
and Taheri, 
2011) 
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1.4 Hypothesis, Aims and Objectives 
 
Whilst no specific function for CYGB has yet been discovered, it appears to be linked to 
the fibrotic process within the liver due the reported changes in its expression in HSC 
on their activation, and could be an important target in the treatment of liver disease. 
It is feasible that ECM protein signalling may play a role in activation of HSCs and CYGB 
regulation via cell surface receptors. This study investigates the effect of cell culture on 
different common ECM proteins, on the activation state and Cygb expression in a 
model HSC lines HSC-T6 and LX-2. 
 
1.4.1 Hypothesis 
 
ECM environment affects HSC phenotype, activation state and Cygb expression within 
HSCs via cell surface receptor signalling. 
 
 
1.4.2 Aims and Objectives 
 To investigate the effect of culture on different ECM proteins on HSC 
phenotype, activation state and Cygb expression. 
 
 
 To investigate the signalling method by which any effect is occurring. 
 
 
 To investigate Cygb expression in in vivo liver injury 
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Chapter 2 
Materials and 
Methods 
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2.1 Chemicals and consumables 
 
Unless otherwise stated, all chemicals and consumables were purchased from Sigma-
Aldrich-UK. 
 
2.2 Cell lines 
2.2.1 HSC-T6 cell line 
 
The HSC-T6 cell line was developed in the Friedman Laboratories due to the need for 
an immortalised HSC cell line and was first reported by Friedman et al. (1997). HSC-T6s 
were created from isolated primary stellate cells from male Sprague Dawley rats, 
maintained as a primary culture for 15 days on plastic dishes. After 15 days 
approximately 2x106 were transiently transfected with lipofectamine containing cDNA, 
then after 5-7 days emerging clones were harvested and plated, and single cell clones 
were isolated and amplified without the use of antibiotic selection. Of more than 20 
clones the one labelled HSC-T6 was expanded for further characterisation based on 
preliminary cytoskeleton analysis, revealing the clone phenotype was closest to 
isolated primary stellate cells. These cells were maintained in culture with 10% foetal 
bovine serum (FBS), penicillin-streptomycin (100µl/ml and 100mg/ml, respectively). 
The phenotype has been reported as stable over forty passages (Vogel et al., 2000). 
HSC-T6 exhibit an activated phenotype, supported by their fibroblast-like shape and 
rapid proliferation in culture. They also express cytoskeleton proteins typical of stellate 
cells in the active state, such as desmin αSMA, glial acidic fibrillary protein and 
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vimentin. HSC-T6 also show retinoid-related parameters similar to those of freshly 
isolated quiescent rat HSC including expression of all six nuclear retinoid receptors 
(Vogel et al., 2000). HSC-T6 cells were kindly provided by Francis Chang at the Institute 
of Cancer Research, Royal Cancer Hospital.  
 
2.2.2 LX-2 cell line 
 
LX-2 cells are immortalised human hepatic stellate cells, developed due to the paucity 
of human tissue for research purposes, coupled with low yields of HSC when isolated 
from a liver. HSC were isolated from liver tissue wedges as described by Friedman et 
al. (1992). Cells were passaged three times, plated at 40% confluency for 24hrs, then 
transfected with pRSVTag encoding for SV40 large T antigen with RSV promoter and 
cultured for 24hrs. The cells were maintained for seven passages until morphologically 
distinct and more proliferative than normal passaged cells. The LX-1 cell line was then 
established from a single clone and the LX-2s by selecting a subculture of LX-1s with 
the ability to grown in reduced serum culture, then growing on a single clone from that 
culture. LX-2s express αSMA and are stimulated by PDGF and TGF-β1, they also express 
discoidin domain receptor 2 (DDR2), promatrix metalloproteinase 2 (MMP-2) and 
relatively small amounts of tissue inhibitors of metalloproteinase 2 (TIMP-2) protein 
and α1(1) procollagen mRNA. LX-2s also have the ability to metabolised retinoids 
(Golubovskaya et al., 2008). LX-2 cells were kindly provided by Christopher Weston, 
IBR, University of Birmingham. 
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2.2.3 Primary rat HSCs 
 
Primary rat HSC cells were a kind gift from Rebecca Aucott from the School of Clinical 
Sciences at the University of Edinburgh. HSCs were isolated from one female Sprague 
Dawley rat. The liver was harvested, cut into ~2-3mm pieces and digested at 37°C with 
collagenase, pronase and DNase for ~20mins. Then the tissue was filtered through a 
Nybolt mesh, and a density gradient set up using optiprep. After centrifugation the top 
cell fragment was plated onto T75 flasks, cultured for ~14days (Iredale et al., 1998). 
 
2.3 Continual Cell Culture 
 
Cell culture was undertaken in a class II tissue culture hood (Aura B4, Bio Air, Italy) 
under sterile conditions. Chemicals and consumables were purchased sterile or 
autoclaved before use in cell culture. 
Cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) - high glucose 
supplemented with 10%(v/v) foetal bovine serum FBS for HSC-T6s, 2%(v/v) FBS for LX-
2s and 20% FBS (v/v) for primary HSCs , 1% v/v penicillin/streptomycin (10,000 units 
penicillin, 10mg streptomycin per ml in 0.9% NaCl) (PAA, Somerset, UK), 1% v/v L-
glutamine 200mM (100x) (PAA, Somerset, UK) and 1% v/v MEM non-essential amino 
acids (100x), in BD Falcon tissue culture treated T25 Flasks with vented caps. Cells were 
maintained at 37°C in 5% CO2 (MCO-15AC, Sanyo, Japan) and passaged at confluence.  
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2.3.1 Cell Cryopreservation 
 
Cells were trypsinised (trypsin-EDTA 1x solution), resuspended in 1ml complete media 
and centrifuged for 3 min at 900 rcf (Rotofix 32, Hettich Zentrifugen, Germany) at 
room temperature. Media was removed and replaced with 3 ml freezing mix (FBS 
containing 1% v/v sterile dimethyl sulfoxide [DMSO]). Cells were resuspended and 
transferred to 1ml cryovials (Nalgene, USA) and placed in a Mr Frosty (Nalgene, USA) 
and stored at -80°C for 24hrs before transferring them to vapour phase liquid nitrogen 
for long term storage. 
 
2.4 Culture on different ECM proteins 
 
HSC-T6 cells were cultured as described above in section 2.3.3 until enough cells were 
accumulated for experimental purposes. Cells were then trypsinised for 5 min at 37°C, 
pooled in serum containing media and spun down at 900 rcf for 3min. Cells were 
resuspended in 1ml of media and a cell count was taken using a haemocytometer to 
determine cell density. Cells were diluted to 100,000 cells/ml for HSC-T6s and primary 
rat HSCs and 300,000 cells/ml for LX-2s and 5 ml of cell suspension was added to each 
T25, 2 ml per well of a 6-well plate, 1 ml per well of a 12-well plate. Four different ECM 
protein surfaces were tested: collagen I, collagen IV, laminin and fibronectin (BD 
BioCoat), alongside normal non-coated T25 flasks. Gelatin was also tested as a coating 
in an addition to the ECM proteins as it is denatured collagen and there is increasing 
research around fibrosis resolution and matrix degradation (section 1.2.4) (Friedman, 
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2008c, Ramachandran and Iredale, 2012). Non-coated flasks were coated with sterile 
0.1% gelatin solution and incubated at 37°C for 30 min, any remaining liquid was 
aspirated off and the flask was washed with phosphate buffered saline (PBS). Cells 
were grown for 48hrs on each surface and then passaged back onto the same surface 
over three passages. After 48hrs of culture, cells were trypsinised and a cell count 
undertaken to determine final cell density per flask. In some experiments collagen I 
solution from rat tail was either diluted into culture media at 10, 20, 40 or 60 µg/ml, or 
used to coat plates at 0.4, 0.8, 1.8, 2.4, 6 and 10 µg/cm2. The collagen coating 
procedure is described in section 2.4.1. Some experiments also required coating of the 
culture surface with laminin (UltraPure, BD Bioscience), this procedure is detailed in 
section 2.4.2 Cells were then cultured for 48 hours and RNA was extracted for real-
time polymerase chain reaction (RT-PCR) or whole cell protein was extracted for 
analysis by western blot (see section 2.12). To investigate the possible interaction 
between collagen I and laminin, six well plates were coated with different amounts of 
collagen I and laminin as follows – 10:0, 10:5, 10:10, 5:10 and 0:10 µg/cm2 collagen I: 
laminin, in these cases, the collagen I coating procedure was followed. 
 
2.4.1 Collagen coating procedure 
 
Stock collagen I solution from rat tail was diluted to the required concentration in 
sterile tissue grade water and was then added 6 well plates for the correct 
concentration per cm2, and incubated for 8hrs at room temperature. The excess fluid 
was removed and the plates dried overnight. The plates were then washed with PBS 
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before cells were seeded on to them. 
2.4.2 Laminin coating procedure  
 
Laminin was diluted to the required concentration in serum free culture medium and 
the appropriate volume added to the 6-well plate for the correct concentration per 
cm2. The plates were then incubated for 1 hr at room temperature. The remaining fluid 
was aspirated off and the plates washed with PBS. Cells were then seeded in to the 
plates. 
 
2.4.3 Mixed matrix effects on HSC-T6 cells 
 
Six well plates were coated as described in section 2.4, HSC-T6 cells were seeded at 
100,000cell/ml, 2 ml per well and cultured for 48hrs then images were taken. 
 
2.5 Cell imaging using Light Microscopy 
 
Cells were imaged on a Nikon Eclipse TS100 light microscope and pictures taken using 
a Canon EOS 7D digital camera 24hrs post seeding at 40x and 400x magnification. 
Images were enhanced using the one step Photo Fix function on Jasc Paint Shop Pro V 
9.00. 
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2.6 Retinoic Acid uptake on different culture surfaces 
 
Glass coverslips were coated with 10 µg/cm2 of either collagen I or 5 µg/cm2 laminin 
(described in section 2.4) or sterilised and put into a well of a six well plate. Cells were 
seeded at 100,000 cells/ml, 2ml per well for HSC-T6s, or 300,000 cells/ml, 2ml per well 
for LX-2s, all trans retinoic acid (ATRA) was diluted to 1µM into the culture media and 
cells were cultured for 48hrs. Cells were fixed in 4% paraformaldehyde and the 
coverslips mounted onto microscope slides using hydromount. Cells were imaged 
using a Leica TSC SP2 confocal microscope (Leica Microsystems) using a 63x oil 
immersion objective NA 1.32, retinoids were excited with an argon laser at 351 nm and 
emission detected at 515 nm. All images were processed in an identical manner using 
AdobePhotoshop PS3E. 
 
2.7 Ribonucleic acid isolation  
 
Total ribonucleic acid (RNA) was isolated using Qiagen RNeasy Miniprep Kit including a 
QiaShredder step and a DNase I step (Qiagen). Briefly, cells were washed with PBS then 
trypsinised at 37 °C for 5 min. Cells were then collected into a 1.5 ml microcentrifuge 
tube in 1 ml of serum containing media and centrifuged at 4000 rcf for 4 min. The 
supernatant was removed and cells were disrupted in 350 µl of Buffer RLT containing 
2-mercaptoethanol (10 µl/ml). The lysate was then pipetted into a QiaShredder and 
centrifuged for 2 min at 13,200 rpm. After the addition of 70% ethanol in a 1:1 ratio 
the sample was then added to an RNeasy spin column and centrifuged at 9,200 rpm for 
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30 sec. The sample was washed with 350 µl RW1 buffer and centrifuged as before. The 
DNase I step was then executed, 10 µl of reconstituted DNase was diluted in 70 µl RDD 
buffer, and this was then added to the spin column and incubated at room 
temperature for 15 min. The sample was then washed with RW1 buffer as previously 
described. The sample was then washed twice with 500 µl RPE buffer, once as 
previously described with RW1 buffer, then centrifuged for 2 min at 9,200 pm. The 
column was then dried by centrifugation at 13,200 rpm for 1 min and RNA eluted into 
30 µl RNAse-free water by centrifugation for 1 min at 9,200 rpm. RNA was quantified 
spectrophotometrically on a Nanodrop ND1000 and stored at -80 °C. 
 
2.8 Complementary DNA synthesis 
 
Complementary DNA (cDNA) was synthesised using Agilent Affinity Script Multitemp 
cDNA synthesis kit utilising oligo (dT) primers (Agilent, UK). Briefly, 0.5 µg of isolated 
RNA was added to 1.0 μl of oligo (dT) primer (0.5 μg/μl) and the reaction volume made 
up to 15.7µl with RNase-free water. The primers were annealed to the RNA by 
incubating the sample at 65° C for 5 min and cooled at room temperature for 10 min. 
The following components were then added to each sample, in order: 2.0 μl of 10× 
AffinityScript RT buffer, 0.8 μl of dNTP (deoxynucleotide triphosphates) mix (25 mM 
each dNTP), 0.5 μl of RNase Block Ribonuclease Inhibitor (40 U/μl) and 1 μl of 
AffinityScript Multiple Temperature RT for a final reaction volume of 20 µl. The 
samples were then incubated for 1 hr at 45 °C then the reaction was terminated by 
incubation at 70 °C for 15 min. The samples were then cooled and stored at -80 °C until 
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required. 
2.9 Quantitative RT-PCR  
 
RT-PCR was conducted using 500 ng cDNA, 1 µl primer-probe (Applied Biosystems or 
Primer Design) and 10 µl qPCR Brilliant III Ultra-Fast QPCR MasterMix (Agilent), made 
up to 20 µl with RNase-free water (Qiagen). The RT-PCR run then consisted of one 
cycle at 95 °C for 3 min, then 50 cycles of 95 °C for 20 sec then 60 °C for 20 sec, during 
which the data was gathered. Table 2.1 shows the TaqMan-style primer sequences. All 
primer-probes were FAM labelled except for hexokinase 1 (HK1) which was VIC 
labelled. HK1 was chosen as the housekeeping gene for RT-PCR experiments based on 
the findings of Wang and Xu (2010), who investigated the expression stability of six 
common house-keeping genes in eight types of hepatic cells, including HSCs, isolated 
at different time points from a liver regenerating after partial hepatectomy. HK1 was 
found to be the most stable gene, along with β-Actin, in HSCs. Amplification of the 
housekeeping gene, HK1 was conducted simultaneously with target gene 
amplification, reactions were undertaken in triplicate and Cts averaged across a 
sample.  
 
2.10 Proliferation Assay 
2.10.1 HSC-T6 manual count time-course 
 
Cells were seeded at a density of 100,000 cells/ml for HSC-T6s and 300,000 cells/ml for 
LX-2s and 5 ml put into a collagen I coated (BD BioCoat) or non-coated (BD 
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Biosciences) T25. Cell counts were taken using a haemocytometer at 8, 24, 32 and 48 hr 
post seeding by trypsinising the cells and centrifuging them as described in section 2.3. 
Cells were then resuspended in 1 ml of media, 100 µl was added to a solution 
containing 100 µl Trypan Blue and 800 µl PBS. This cell suspension was mixed well then 
20 µl was added to both chambers of the haemocytometer. Five counts from each 
chamber were taken and averaged and total cell density per flask determined. 
 
2.10.2 Cell IQ analysis for HSC-T6 cells and LX-2 cells 
 
HSC-T6 cells were seeded 100,000 cells, and LX-2 cells at 300,000 cells, per well on 
collagen I coated, laminin coated or non-coated wells of a 24-well plate, coating with 
matrix protein was conducted as described in section 2.4.1 and 2.4.2. Cells were 
allowed to settle for 10 min at room temperature and then placed in the CellIQ (C M 
Technologies, UK) at 37 °C, 5 % CO2 for 72 hrs, images of the cells were taken every 15 
sec. CellIQ Analyser software was used to create videos and estimate cell number 
across the culture period. 
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Table 2.1: Details Of TaqMan Style Primer-Probes used in this Study 
Gene Species Company Forward (Sense) Reverse (Anti-sense) 
Cytoglobin (Cygb) Rat Applied 
Biosystems 
n/a Unique Assay ID: Rn00590627_m1 
Primer 
Design Ltd 
CCCCGTGTGTACCCCTT
G 
AAAGACAGGCAGTTAC
AGGAAG 
α Smooth Muscle 
Actin (αSMA) 
Rat Applied 
Biosystems 
n/a Unique Assay ID: Rn01759928_g1 
Discoidin Domain 
Receptor 1 (DDR1) 
Rat Primer 
Design Ltd 
TGATTACAGACTACAT
GGAGAACG 
GGAAGCCCCTGAGTGA
CC 
Discoidin Domain 
Receptor 2 (DDR2) 
Rat Primer 
Design Ltd 
TCATCCTGCTGGCTGT
CAT 
GCTAACTGTCATTTCAT
CATCCA 
Integrin Beta 1 
(β1) 
Rat Primer 
Design Ltd 
TCTGATGAATGAAATG
AAATGAGGAGGAT 
TTGCTGGTGTTGTACTA
ATGTATG 
Integrin alpha 11 
(α11) 
Rat Primer 
Design Ltd 
CCTCTGCTTCGGACCT
ATCTT 
CCGTGGCATATACCGT
CTCT 
Integrin alpha 2 
(α2) 
Rat Primer 
Design Ltd 
CAGCACCAGTTTCTTG
AAGGA 
GCGAACCAACAATCAC
ATCATT 
Integrin Beta 4 
(β4) 
Rat Primer 
Design Ltd 
CAGGGTGGAGAAGAC
TACGA 
ACCAGGTGCTCAGTGT
CAT 
Integrin alpha 6 
(α6) 
Rat Primer 
Design Ltd 
CCGCCGCTCAGAATAT
CAAG 
CCACCACGCTATCCCTG
AA 
Integrin alpha 5 
(α5) 
Rat Applied 
Biosystems 
n/a Unique Assay ID: 01761831_m1 
Focal Adhesion 
Kinase (Ptk2) 
Rat Primer 
Design Ltd 
AGTGAAGACAAAGAC
AGGAAAGG 
GATCAGGTCCAGCCAT
GTTCTC 
Integrin Beta 3(β3) Rat  Applied 
Biosystems 
n/a Unique Assay ID: 00596601_m1 
Hexokinase 1 
(HK1) 
Rat Applied 
Biosystems 
n/a Unique Assay ID: Rn00562436_m1 
Primer 
Design Ltd 
CCCTGCCGAATCCAAG
A 
CATCATAGTCCCCTCG
CTTCT 
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2.11 Whole Cell Protein Isolation 
2.11.1 Buffers 
 
6x laemmli buffer: 418 mM SDS (sodium dodecyl sulfate), 867 µM bromophenol blue, 
47 % v/v glycerol, 60 mM Tris-HCl pH 6.8, 1.6M 2-mercaptoethanol, made up to 
volume with ddH2O and stored at -20 °C.  
RIPA buffer: Tris-HCl pH 7.5 (25 mM) NP-40 (1 % v/v) NaCl (150 mM), sodium dodecyl 
sulfate (0.1 % v/v), sodium deoxycholate (1% w/v) and mammalian protease cocktail 
inhibitor (10 µl/ml). 
 
2.11.2 Procedure 
 
HSC-T6 cells were seeded at 100,000 cells/ml, 2 ml per well, and cultured on 
noncoated or collagen I coated (BD BioCoat) six well plates for 48 hrs. For analysis of 
Cygb protein cells were lysed directly in RIPA buffer, incubated on ice with agitation of 
15 min, centrifuged for 10 min at 4°C and the supernatant removed and stored at -
80°C until required. For analysis of phosphorylated focal adhesion kinase (pFAK) 
protein was extracted directly into 500 µL 6x Laemmli Buffer warmed to 60 °C, by 
means of a cell scraper. Samples were sonicated 4 times and heated to 95 °C for 3 min 
and stored at -80 °C until required.  
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2.11.3 Bradford assay for protein quantification 
 
Estimates of protein concentration from whole cell extracts into RIPA buffer were 
undertaken using the Bradford method (Bradford, 1976), using BSA (1-10 µg) as a 
standard. 
 
2.12 Western blot for Cygb and phosphorylated FAK 
2.12.1 Buffers 
 
1X TBS: Tris base (20 mM) and NaCl (0.15 M), adjusted to pH 7.5 
1X TBS-0.05% Tween 20: Tris base (20 mM), NaCl (0.15 M) and Tween 20 (0.05 %), 
adjusted to pH 7.5. 
SDS-PAGE running buffer: Tris base (25 mM), glycine (192 mM), and SDS (0.1 %). 
Transfer buffer: Tris base (20 mM), glycine (150 mM) and methanol (20% v/v). 
Blocking buffer: Low-fat powdered milk (Marvel, U.K.), or bovine serum albumin (BSA), 
(5% w/v) in 1X TBS-0.05 % Tween 20  
 
2.12.2 Gels 
 
12.5 % Resolving gel: Acrylamide:bisacrylamide 30 % solution (12.5 %) (Geneflow, UK) 
Tris-HCl pH 8.8 (375 mM), (Fischer Scientific, UK) SDS (0.1 %). Immediately prior to 
casting N,N,N,N-tetramethylethylenediamine (TEMED) (15 μl per 10 ml) and 10% w/v 
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ammonium persulfate (APS) (150 μl per 10 ml) were added. 
 
2.12.3 Assay procedure 
 
For protein analysis by western blot, either 30 µl of protein extract for pFAK 
investigation, or 20 µg total protein in RIPA buffer, incubated for 5 min at 95 °C with 
laemmli buffer diluted to 1x concentration, for Cygb investigation, was resolved on a 
12.5 % SDS-PAGE electrophoresis gel at 120 V for 90 mins and transferred to a PVDF 
(polyvinylidene difluoride) membrane (Millipore) by means of a mini trans-blot 
electrophoretic transfer cell (Bio-Rad), at 100 V for 120 min at 4°C. Blocking was 
achieved by incubating the PVDF membrane with blocking buffer, for 16 hrs at 4°C for 
pFAK or 1hr at room temperature for Cygb, on a rocking platform (Stuart Scientific 
STR9, U.K.). The membrane was then incubated with polyclonal antibody (Ab) against 
Focal Adhesion Kinase (FAK) pY397 raised in mouse (BD Bioscience) 1:500 diluted in 
blocking buffer or polyclonal Ab against Cygb raised in rabbit (Santa-Cruz) 1:200 or 
polycolonal Ab against βActin raised in mouse (Sigma) 1:10000 diluted in blocking 
buffer, for 1 hour at room temperature for pFAK and β-actin, or overnight at 4 °C for 
Cygb, on a rocking platform at room temperature. The membrane was washed three 
times in  1X TBS-0.05% Tween 20 solution for 10 min each time, then incubated with a 
horseradish peroxidase (HRP)-conjugated anti-mouse secondary antibody (1:500 
dilution, DAKO, U.K.) for pFAK and β-actin or conjugated anti-rabbit antibody (1:1000 
dilution, DAKO, UK) in blocking buffer at room temperature for 1hr. 1X TBS-0.05% 
Tween 20 solution was used to wash again (2 × 10mins), followed by a final wash in 1X 
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TBS for 10min. The membrane was then incubated with SuperSignal West Pico 
Enhanced Chemiluminesence (ECL) Substrate (Thermo Scientific) for pFAK and β-actin, 
or Westar Supernova Femto ECL Substrate (Geneflow, UK) for Cygb prepared as per 
manufacturer’s instructions. Protein bands were visualised via exposure to ECL 
hyperfilm (Amersham Biosciences) and development in an X-ograph machine (AGFA 
Curix60). 
 
2.13 Exploration if the effects of collagen I 
 
Several assays were conducted to explore the effects of collagen I on Cygb expression 
in HSC-T6 cells, a time course was conducted over 48 hrs, with cell counts and RNA 
extracted as previously described in 2.7, at 8, 24, 32 and 48 hr. Cells were seeded at a 
density of 100,000 cells per ml, 5ml per flask onto non-coated (BD Biosciences) or 
collagen I coated T25 flasks (BD BioCoat). RT-PCR was conducted as described in 
sections 2.8 – 2.9. 
Two concentration response assays were conducted to investigate whether 
attachment to collagen was necessary for the effects on Cygb to occur. Collagen I 
solution from rat tail was either diluted into culture media at 10, 20, 40 or 60 µg/ml, or 
coated on to 6 well plates (BD) at 0.4, 1.8, 2.4, 6 or 10 µg/cm2, as described in section 
2.4.1. Cells were cultured for 48 hrs and RNA was extracted as in 2.7 and RT-PCR 
conducted as in 2.8 and 2.9, RNA from cells grown on a pre-coated collagen I (BD 
BioCoat) positive control was also extracted. 
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2.14 pFAK expression and pFAK Inhibition Assays 
 
MTT cell viability studies were conducted using FAK Inhibitor 14 (FAKI) (Tocris) prior to 
flow cytometry and confocal microscopy investigation. 
 
2.14.1 4 3-(4,5-Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) 
reduction assay 
 
MTT is a water soluble dye, which is yellow in colour and able to cross cell membranes. 
In the cell it is reduced by mitochondrial succinate dehydrogenase producing an 
insoluble crystalline formazan product. When dissolved in DMSO the formazan crystals 
form a purple solution allowing quantification of cell viability via a colorimetric assay, 
by measuring the absorbance of the solution between 500 and 570 nm. The greater 
the absorbance reading, the greater the number of viable cells. 
 
2.14.2 Assay procedure 
 
Cells were seeded at 100,000 cell/ml, 100µl per well of both a non-coated (BD) and a 
collagen I coated (BD BioCoat) 96 well plates. Cells were incubated with either 0, 1, 10, 
50 or 100 µM, or 0, 0.05, 0.1, 0.5 or 1µM FAK Inhibitor 14 (FAKI) for 46hrs. Cells were 
washed with PBS (200µl) and 100 µl fresh medium was added along with 10 % 3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) (0.5 mg/ml final 
concentration). Following incubation at 37 °C for hrs in a humidified chamber the 
medium was removed and DMSO was added (200 µl) to dissolve the blue formazan 
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product. The absorbance was determined immediately at 570 nm using a Bio-Tek 
FL600 plate reader (Bio-Tek Instruments Inc. U.S.A.) against a DMSO blank. 
Concentrations 0.1, 0.5 and 1 µM were then taken forward to confocal microscopy and 
flow cytometry analysis, with cell cultured on non-coated (BD) or collagen I coated (BD 
BioCoat) 6-well plates.  
 
2.14.3 Flow cytometry for pFAK and FAKI   
 
HSC-T6 cells were cultured as described in section 2.4 on non-coated and collagen I 
coated plates. FAKI diluted to the desired concentration was added to the media for 
the final 24 hrs of culture. At 48hrs cells were trypsinsed, centrifuged as before and 
resuspended in 4 % paraformaldehyde for 1 min on ice. Cells were then spun down 
and the fixative removed and replaced with 90 % methanol at -20 °C for 10 min, and 
stored at 20 °C until required. 
For analysis by flow cytometry, 2 ml of blocking buffer (3 % FBS in PBS) was added to 
the cell suspension and cells were rinsed by centrifugation (3 min at 900 rcf) twice. 
Cells were blocked by incubation in 100 µl blocking buffer for 10 min with agitation. 
pFAK Y397 Ab (BD Bioscience) was added to a final concentration of 1 µg/ml and 
sample were incubated at room temperature for 1 hr. Samples were then rinsed by 
centrifugation as before, then 100µl of FITC (fluorescein isothiocyanate) conjugated 
anti-mouse 2° Ab (Dako, UK) diluted 1:20 in incubation buffer was added and samples 
were incubated in the dark for 30 min at room temperature with agitation. Cells were 
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then rinsed as before and resuspended in 500 µl PBS for analysis by flow cytometry. 
FITC fluorescence of 10,000 live cells was analysed using a BD FACScalibur™ (BD 
Bioscience) and Weasel software (Walter and Elisa Hall Institute of Medical Research, 
Australia) was used for data analysis. 
  
2.14.4 Confocal microscopy for pFAK and FAKI 
 
Cells were set up as described in 2.14 and were grown for 48 hrs or treated with FAK I 
as outlined in section 2.14.2. Cells were then fixed as described in section 2.14 and 
permeabilised with 4 °C 90 % methanol and washed with twice with PBS. Samples 
were then blocked in blocking buffer for 30 min at room temperature on a rocker. 
Blocking buffer was removed and cells were incubated with pFAK Y397 (BD Bioscience, 
UK) 1°Ab diluted to 5 µg/ml for 1 hr at room temperature. Samples were then rinsed 
twice in incubation buffer and incubated in the dark in FITC conjugated anti-mouse 
2°Ab (Dako, UK) diluted 1:200 in blocking buffer for 1 hr at room temperature. Cells 
were then rinsed three times in PBS and the nuclei were counter-stained by adding 
200 μl of 2 μg/ml Hoechst 33342 in 1× PBS 15min before imaging. Slides were 
mounted using 50 μl of hydromount and stored in the dark at 4  C until required. Cells 
were then imaged on the Leica confocal microscope (Leica Microsystems) using a 63x 
oil immersion objective NA 1.32, the excitation wavelength was 405 nm for Hoechst 
33342 and 488 nm for FITC. All images were processed in an identical manner using 
Adobe Photoshop PS3E.  
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2.15 Intracellular ROS assay with 2',7'-dichlorodihydrofluorescein diacetate (H2DCF-
DA) 
 
Cells were seeded 100,000 cells/well on collagen I coated, laminin coated or non-
coated wells of a 24-well plate, coating with matrix protein was conducted as 
described in section 2.4.1 and 2.4.2, and grown for 45 hrs. Positive control wells were 
then treated with 10 µM H2O2 for 1hr. At 46hrs H2DCF-DA was added to the wells to a 
final concentration of 10 µM and cells were incubated for 2 hrs at 37°C. Cells were 
then trypsinised for 10 min at 37°C to obtain a single cell suspension, then the cells 
were pelted by centrifugation for 3 min at 900 rcf. The cell pellet was resuspended in 1 
ml of PBS and the samples analysed for fluorescence as described in section 2.14.3. 
 
2.16 RNA inhibition (RNAi) of FAK 
2.16.1 Optimisation of RNAi 
 
HSC-T6 cells were seeded at 50,000, 100,000 or 200,000 cells/ml, 2 mls per well in 
antibiotic-free culture media, in a non-coated 6-well plate and cultured for 24hrs 
before transfection with short interfering RNA (siRNA) - either targeting FAK (Ptk2), 
non-targeting negative control (NT2 and NT4) (Thermo Scientific, UK) or untreated. 
Resuspension of siRNA was conducted according to instructions; tubes were briefly 
centrifuged resuspended in 1x siRNA buffer (5x siRNA buffer [Thermo Scientific, UK] 
diluted 1:5 with RNAase-free sterile water [QIAGEN, UK]) to a final stock concentration 
of 20 µM. The solution was pipetted up and down 3—5 times, and placed a shaker for 
90min at room temperature. Tubes were centrifuged and aliquoted for storage at -
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20°C until required. siRNA was prepared as recommended in Opti-MEM 1 media (Life 
Technologies, UK) and DharmaFECT solution 1 (Thermo Scientific, UK). For 
optimisation, four different volumes of DharmaFECT were tried—1, 2, 4 and 6 µl. Stock 
siRNA was diluted to 5 µM in Opti-MEM and then further diluted 1:20, 200 µl of this 
solution was used per well. In a separate tube, the appropriate volume of DharmaFECT 
was prepared in Opti-MEM, for a final volume of this solution of 200 µl per well. The 
tubes were mixed by pipetting then incubated at room temperature for 5min, then the 
two tubes were combined for a final volume of 400 µl per well. This solution was 
mixed by pipetting and incubated a room temperature for 20 min, and then 1600 µl of 
antibiotic-free culture media was added for a final siRNA concentration of 25 nM. 
Culture media was replaced with transfection media and cells were cultured for 24 hrs, 
transfection media was then replaced with culture media and culture continued for a 
further 24 hrs. RNA was then extracted as described in section 2.7 and RT-PCR 
conducted as outlined in section 2.8 and 2.9 to determine optimal RNAi conditions. 
 
2.16.2 Optimised RNAi 
 
Results of the RNAi optimisation experiment revealed that 4µl of DharmaFECT and 
200,000 cells/ml provided optimal conditions of interference of Ptk2 RNA with the 
fewest off-target effects. Therefore, these conditions were used in all future 
experiments, where cells were set up as described in section 2.16.1, but cultured on a 
collagen I coated surface (see section 2.4.1) as well as non-coated plastic. The 
experiment was continued as described in 2.16.1 and then RNA extracted as described 
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in section 2.7 and RT-PCR conducted as outlined in section 2.8 and 2.9, samples were 
then analysed for FAK and Cygb expression. 
 
2.17 In vivo mouse models of liver disease 
 
RNA samples from mouse models of liver disease were a kind gift from Dr Christopher 
Weston from the University of Birmingham. Details of the disease models and sample 
preparation are given below Animal studies were performed in accordance with the UK 
Animals (Scientific Procedures) Act of 1986 with approval granted by the UK Home 
Office (project license PPL 40/3201, Shrewsbury office) (Weston et al., 2014). 
 
2.17.1 CCl4-induced liver fibrosis in murine models 
 
Mice were maintained under conventional conditions at the Biomedical Services Unit, 
University of Birmingham, and in accordance with the UK Animals (Scientific 
Procedures) Act of 1986 and were injected twice weekly for 8 weeks with either CCl4 
(1.0 ml/kg CCl4 diluted 1:4 in mineral oil) or mineral oil alone as a control. Animals 
were sacrificed 96hr after the final dose of CCl4 by cervical dislocation after 
withdrawing blood samples by cardiac puncture during isoflurane anaesthesia. Livers 
were dissected and tissue was stored in RNAlater (Qiagen, UK) until RNA extraction 
was conducted.  
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2.17.2 Murine models of steatohepatitis 
 
Mice were maintained as described in section 2.17.1, there were five mice housed per 
cage at 23oC under an alternating light-dark cycle of 12hrs duration. For methionine 
choline deficient diet (MCD) induced liver disease mice were fed the MCD diet (MP 
Biomedicals, UK) ad libitum for 4-6 weeks. For the western lifestyle model of liver 
disease (WLM) mice were fed a diet consisted of 45 % calories coming from fat, and 
30% of the fat was in the form of partially hydrogenated vegetable oil (Harlan 
Laboratories, US. Custom Research Diet TD.06303), these mice also received fructose 
supplemented drinking water (55 % fructose, 45 % glucose by weight at a 
concentration of 42 g/L) ad libitum for either 6, 9 or 12 months. Control animals 
received normal chow (NC) and non-supplemented drinking water. Mice were 
sacrificed and livers processed as stated in section 2.17.1. 
 
2.18 Protein and RNA extraction from human liver tissue 
 
Protein was extracted from human liver tissue blocks weighing 70-90 mg. Samples 
were cut, placed into separate M-tubes (MiltenyiBiotec) and cells lysed in 20 µl of 
CelLyticMT buffer per mg tissue containing 1x protease inhibitors (Complete ULTRA, 
Roche, 2x stock made from 1 tablet in 5 ml CelLytic MT), 1x PhosSTOP phosphatise 
inhibitor (Roche, 10x stock made from 1 tablet in 1 mL CelLytic) and 5 U/ml DNase-I 
(Roche on program Protein-01 in GentleMACS (MiltenyiBiotec). Extracts were then 
centrifuged at 1000 x g for 2 min, to collect the protein sample. The whole supernatant 
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was then transferred to a labelled microcentrifuge tube and placed on a Vibraplatform 
at 4 oC to shake the samples for 1 hr. The suspension was centrifuged in a 
microcentrifuge at 13,000 rpm for 10 mins, and the supernatant was then transferred 
to a clean microcentrifuge tube and kept on ice, the volume was made up to 500 µl 
with CelLyticMT. Protein concentration was determined using the BCA/Biuret assay 
and samples stored in aliquots at -80 oC. 
 
For RNA extraction ~20 mg of tissue was cut and transferred to a gentleMACS M-tube. 
A Qiagen RNEasy kit was used to extract RNA, 600 µl of RLT buffer (containing 2-
mercaptoethanol) and the tissue was disrupted using the GentleMACS. Samples were 
centrifuged at 800 x g for 2 mins and transferred to a microcentrifuge tube then 
centrifuged again at top speed for 3 mins. The supernatant was transferred to a new 
microcentrifuge tube and 1 volume of 70 % ethanol was added and mixed immediately 
by pipetting. 700 µl of sample, including precipitate, was transferred to a mini column 
in a 2ml collection tube. Samples were spun at >8000 x g for 15 secs, and flow through 
discarded, 350 µl buffer RW1 was added and samples were centrifuge for 15 secs at 
>8000 x g. 10 µl DNaseI was added to 70 µl buffer RDD and mixed by inverting, the 
DNase I mix was applied to the RNeasy spin membrane and incubated at room 
temperature for 15 mins. 350 µl buffer RW1 was added to the samples and they were 
centrifuged for 15secs at >8000 x g. Flow through was discarded and 500 µl buffer RPE 
was added to the sample and it was centrifuged for 15 secs at >8000 x g. Flow through 
was discarded, 500 µl buffer RPE added and samples were centrifuged for 2 mins at 
>8000 x g. The spin column was transferred to a new 2 ml tube and centrifuged at full 
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speed for 1min to dry the column. The column was then transferred to 1 ml collection 
tube. 40 µl of RNase-free water was added directly onto the silica-gel membrane and 
samples were spun for 1min at >8000 x g, this process was repeated, the concentration 
of RNA was determined and samples were stored at -80 oC until needed. 
 
2.19 Human tissue section staining 
 
After local ethics committee approval, human tissue and blood samples were collected 
from consenting patients attending the University Hospitals Birmingham and 
Newcastle upon Tyne Hospitals NHS Foundation Trusts. Tissue samples were obtained 
from patients, in accordance with local ethics committee approval (REC reference, 
06/Q2702/61) with informed consent. Liver tissue that was surplus to surgical 
requirements from explanted livers for a normal organ donor, or from uninvolved liver 
removed at hepatic resection for secondary liver tumours; Patients undergoing liver 
transplantation for chronic liver disease provided diseased tissue.  
Acetone fixed, fresh frozen sections (10 μm thickness) from normal and diseased livers 
were defrosted and warmed to room temperature. They were immediately refixed in 
acetone for 5 mins and transferred into TBS-Tween buffer (TBS pH 7.6 + 0.05 % 
Tween20) for 5 mins. The Endogenous peroxidases were blocked by incubation with 
0.3% hydrogen peroxide in methanol and slides were washed in TBS-Tween buffer for 
5mins. Samples were then incubated for 20 mins in normal blocking serum (10 % FCS 
in TBS Tween), then 1°Ab in TBS Tween buffer plus 2% FCS in a humidified chamber, 
overnight at 4°C (Cygb – Santa Cruz 0.2 mg/ml stock 1:200 dilution, IgG - rabbit control 
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0.2 mg/ml stock 1:200 dilution). Slides were then washed twice for 5mins in TBS-
Tween buffer and incubated for 30mins with ImmPRESS rabbit/universal reagent 
(Vector Labs) then washed as before. NovaRed (Vector Labs) reagent was prepared 
according to manufacturer’s instructions; 3 drops of reagent 1 was added to 5ml of 
distilled H2O and mixed well then 2 drops of reagent 2 were added and mixed, 2 drops 
of reagent 3 were added and mixed and finally 2 drops of H2O2 were mixed in. Sections 
were incubated in NovaRed until desired intensity developed (between 10 and 30 
mins) and sections washed in TBS Tween as before. Slides were counter-stained with 
Mayers haematoxylin for 30secs and rinsed in tap water. Finally sections were 
dehydrated through alcohol and clearene, mounted with DPX (Distrene 80, Plasticizer 
and Xylene) mountant and left to dry. Stained sections were visualised using a Zeiss 
Axioskop 40. Images were captured with an Axiocam MRc5 and subsequently 
processed with AxioVision software (Carl Zeiss MicroImaging Inc.). 
 
2.20 Statistical Analysis 
 
Quantitative real-time RT-PCR was analysed using the Pfaffl method (Pfaffl, 2001). 
Primer efficiencies were estimated using either a standard curve or linReg PCR 
software. Data was assessed for normality (Anderson-Darling) and then analysed using 
one-way ANOVA, students –t test, Kruskall-Wallis or Mann-Whitney U tests using 
Minitab 16 software. Error bars are given as +/- standard error of the mean (SEM). 
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Chapter 3 
CYGB expression in 
liver disease 
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3.1 Introduction 
 
The first indication that Cygb could have a role within the fibrotic process in the liver in 
vivo was reported by Kawada et al. (2001), who observed upregulation of Cygb in 
activated HSC in thioacetamide induced liver fibrosis in rats, it was then characterised 
in the human liver by Asahina et al. (2002). There is much debate around the cellular 
and sub-cellular location of CYGB within the liver which is discussed in section 1.1.5, 
however there is a general agreement that it is upregulated during fibrosis, whether in 
the liver or in other organs (section 1.1.8). In this chapter, observations of Cygb 
expression in mouse models of liver disease and also diseased human liver are 
presented. 
 
3.2 Results 
3.2.1 Cygb RNA expression in murine models of liver disease 
 
Cygb RNA expression was analysed in three mouse models of liver disease; CCl4-
induced liver fibrosis, methionine choline deficient diet (MCD), a model of NASH, and 
western lifestyle model of liver disease (WLM). All models of liver disease showed 
significant upregulation of Cygb RNA, shown in Figure 3.1 A-C. In CCl4 induced liver 
fibrosis, Cygb is significantly upregulated compared with mineral oil treatment, with 
expression five times that of the control (p=0.016 two-tailed t-test) (Figure 3.1 A). In 
the MCD diet, Cygb expression in the liver was also five-fold greater than in mice fed a 
normal diet (p=0.040 two-tailed t-test) (Figure 3.1 B). Interestingly, the treatment that 
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had the most marked effect on Cygb expression in the liver was in WLD, where an 
eight-fold increase was observed (p<0.01 two-tailed t-test) (Figure 3.1 C). 
 
3.2.2 CYGB expression in different disease pathologies in human liver 
 
Observations of CYGB expression in different human liver pathologies were made by 
RT-PCR, western blot and immunohistochemistry. Samples were matched so RT-PCR, 
western blot and immunohistochemistry were performed on samples from the same 
liver, for each disease, only one liver was analysed, therefore no statistical analysis was 
possible. The diseases investigated were: alcoholic liver disease (ALD), autoimmune 
hepatitis (AIH), primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC) and 
non-alcoholic fatty liver disease (NASH), Figure 3.2 A shows the results of the RT-PCR 
analysis of the whole liver RNA extracts from a sample of these diseases, CYGB 
expression is depicted relative to expression in a donor liver and all diseases analysed 
showed upregulation of CYGB. ALD and PSC exhibited a doubling in CYGB expression, 
where as both PBC and NASH showed an approximately two fold increase, AIH had the 
most marked increase in CYGB expression with an approximately six fold increase. 
Western blot analysis of protein expression (Figure 3.2 B) doesn’t give any indication of 
relative differences in CYGB expression between diseases; however there are three 
protein bands at different weights, ~25 kDa, ~70 kDa and ~80 kDa and these proteins 
of different weights are differentially expressed between donor and diseased whole 
liver lysates and also the liver diseases themselves. Most obviously the donor liver 
sample has a single dark protein band at around 70 kDa, where as all the diseased liver 
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samples have a band at around 80 kDa, which is not present in the donor liver. Other 
notable observations are that the ALD liver only contains a single protein band at 
approximately 80 kDa, and no other bands are visible in this sample, the NASH liver 
sample also exhibits a dark band at around 21 kDa, the other liver disease samples, 
except for ALD, contain a faint band at this weight, but the protein at this weight in 
NASH is notably upregulated. 
Immunohistochemistry analysis of these samples (Figure 3.3) again revealed 
interesting results (see appendix 1 for immuno-matched controls, which show no 
staining). CYGB is expressed in the donor liver in hepatocytes, and mainly in the 
cytoplasm of these cells, although some nuclear staining is visible. CYGB expression 
investigated by immunohistochemistry in the diseased livers appears to be 
upregulated compared with the donor liver, and is mostly associated with fibrotic 
regions, where HSCs are found, in the cytoplasm of cells. Infiltrating cells are negative 
for staining, suggesting these cell types do not express CYGB. There is also some 
staining evident in non-fibrotic regions of tissue in hepatocytes, this is especially 
evident in PSC, where staining overall is much darker than in the other disease sections 
or in the donor liver. In the NASH liver sample there is also staining visible around bile 
duct. Different disease pathways, although mechanistically different converge on the 
same stress response pathway, which involves HSC activation; here evidence is 
presented showing that upregulation of CYGB is also part of this stress response in 
several disease pathways.
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Figure 3.1: Fold change in Cygb gene expression by RT-PCR analysis of RNA extractions from whole mouse liver 
from models of liver disease A) CCl4 treatment B) MCD treatment C) WLD treatment. N of at least 3 per treatment, 
+/- SEM
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Figure 3.2: Investigation of CYGB expression in human liver diseases by A) RT-PCR analysis of whole liver RNA 
extractions, B) Western blot analysis by 12.5% SDS electrophoresis of whole liver protein lysates and Abbreviations: 
CYGB = cytoglobin,, NASH = non-alcoholic fatty liver disease, PBC = primary biliary cirrhosis, PSC = pulmonary 
sclerosing   cholangitis, ALD = alcoholic liver disease, AIH = autoimmune hepatitis. N=1 
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Figure 3.3: Immunohistochemistry analysis of frozen liver sections with CYGB antibody 1:200. Abbreviations: CYGB 
= cytoglobin, NASH = non-alcoholic fatty liver disease, PBC = primary biliary cirrhosis, PSC = pulmonary sclerosing   
cholangitis, ALD = alcoholic liver disease, AIH = autoimmune hepatitis. N=1
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3.3 Discussion 
 
In vivo observations of Cygb expression in murine models of liver disease and in 
diseased human liver tissue indicate that it is upregulated at both the RNA and protein 
level in the liver as a whole. However, in the current study, levels of RNA and protein 
do not seem to correlate across human liver diseases, however only one sample of 
each disease was analysed, and the donor liver sample came from a different person, 
and therefore the levels of variability between samples or within diseases cannot be 
quantified. The other factor to take into account is that these samples, both mouse 
and human, are from whole livers, and are not from specific cell types within the liver. 
Cygb has been reported to be HSC specific (Kawada et al., 2001, Asahina et al., 2002, 
Schmidt et al., 2004, Motoyama et al., 2014), here staining is observed in hepatocytes 
and more greatly fibrotic regions, with which HSCs are associated (Narmada et al., 
2013). If this HSC specificity was indeed the case, then the increase in Cygb observed in 
liver fibrosis could just be an artefact of the increased numbers of HSC present in a 
fibrotic liver. However initial studies on Cygb reported it to be upregulated in activated 
HSC compared with quiescent HSC (Kawada et al., 2001, Asahina et al., 2002), so as 
well as there being more HSCs, Cygb might also be upregulated within activated HSCs, 
increasing its expression further in a fibrotic liver. However, there is debate over which 
cell types in the liver express CYGB, with several authors reporting observing 
expression in hepatocytes (Geuens et al., 2003, Shigematsu et al., 2008, Yang et al., 
2011), which is also true of this study, therefore, the issue remains unresolved. Indeed 
Burmester and Hankeln (2014) have commented that caution must be taken when 
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attempting to identify cellular localisation of CYGB by antibody validation, owing to the 
quality of available antibodies. If indeed CYGB is expressed in hepatocytes as well as 
HSCs then the observed upregulation in fibrotic livers suggests a function for CYGB 
within the fibrotic process. Observations from immunohistochemistry analysis in this 
report (Figure 3.3) indicate that, although CYGB is not specific to the fibrotic regions, it 
is more highly associated with these areas of the liver tissue than the tissue containing 
no fibrosis. This is further evidence for a role for CYGB in fibrosis, as discussed in 
section 1.1.8.2. Given the clear involvement of CYGB in the fibrotic process, reported, 
though disputed, HSC specificity, the involvement of HSCs in the progression of fibrosis 
and the remodelling of ECM to form the hepatic scar, the effect of ECM on HSC and on 
Cygb expression in HSC was explored in Chapters 4 and 5. 
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Chapter 4 
Effect of ECM on HSC 
phenotype 
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4.1 Introduction 
 
Far from only being the scaffold it was once thought to be, the ECM has an active role 
in the behaviour of the cells of the liver (Reeves and Friedman, 2002) . It is now 
recognised that the ECM plays an important role in the activation of HSC, as well as 
providing structure for adhesion and acting as a reservoir for cytokines, there is 
evidence for ECM itself signalling to HSC (Reeves and Friedman, 2002). Friedman et al. 
(1989) reported that primary rat HSC cultured on a basement membrane type matrix; 
Engelbreth-Holm-Swarm (EHS), which is laminin rich, maintained a quiescent 
phenotype compared with those cultured on plastic. Priya and Sudhakaran (2008) 
reported that retinol uptake ability and synthesis of collagen and proteoglycan in 
primary rat HSC varied depending on culture substrate, with cells grown on collagen I 
showing a more activated phenotype and lower rate of apoptosis compared with those 
on collagen IV and laminin. Carloni et al. (1996) also reported that primary human HSC 
show lower adhesion to laminin I than collagen I and collagen IV. Collagen I is the 
predominant ECM protein in a fibrotic liver (Friedman, 2008a) where as ECM in a 
normal liver is dominated by collagen IV and laminin (Martinez-Hernandez and 
Amenta, 1995). 
With this in mind, the aim of this study was to further investigate the phenotypic 
effects of different ECM substrates on HSC cell lines and primary HSCs and relate any 
observed changes on expression and regulation of Cygb (Chapters 4 and 5). 
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4.2 Results 
4.2.1 Different ECM proteins affect the morphology and proliferation of HSC-T6 cells 
 
HSC-T6 cells were cultured on different ECM protein coated surfaces; collagen I, 
collagen IV, fibronectin, laminin and gelatin as well as non-coated plastic. Images taken 
24hrs post seeding at 100,000 cells/ml show that culture on laminin has a marked 
effect on HSC-T6 cells attachment, morphology and proliferation (Figure 4.1F), with 
cells not exhibiting the elongate shape observed on the other substrates (Figure 4.1 A-
E). Cells cultured on laminin are rounded, and have not flattened like those grown on 
other substrates; cells on laminin also appear to be lower density, single, and not 
clustered, suggesting they divide more slowly. 
 
4.2.1.1 Culture on mixed collagen I and laminin matrices alters the observed 
morphology in HSC-T6 cells 
 
Figure 4.2 shows the effects of mixed collagen I and laminin matrix on the morphology 
of HSC-T6 cells in the presence of both proteins as a growth matrix. Increasing 
amounts of laminin appear to effect cell size and the shape of a minority of cells in the 
presence of both laminin and collagen I (Figure 4.2B to D) where their morphology 
appears similar to those cultured on laminin alone (Figure 4.2E). However the presence 
of collagen, even at lower concentrations, where the concentration of laminin is 
greater (Figure 4.2-D), appears to dominate over laminin.
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Figure 4.1: HSC-T6 cell morphology on different ECM proteins. Cells were imaged 24hrs post seeding at 400x 
magnification. Enhanced using the one step Photo Fix function on Jasc Paint Shop Pro V 9.00. A) Non-coated. B) 
Gelatin. C) Collagen I. D) Collagen IV. E) Fibronectin. F) Laminin. 
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Figure 4.2: Images of HSC-T6 cells cultured on mixed matrix surfaces of collagen I and laminin in differing 
concentrations 48hrs post seeding at 400x magnification. A) 10:0 µg/cm
2
B) 10:5 µg/cm
2
 C) 10:10 µg/cm
2
D) 5:10 
µg/cm
2
 E) 0:10 µg/cm
2
 collagen I: laminin and F) non-coated control. 
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4.2.2 Proliferation of HSC-T6 cells is affected by ECM  
 
Observation of HSC-T6 in culture on different ECM substrates indicated that 
proliferation was affected by culture on these proteins. To this end, end point cell 
counts and Cell-IQ analysis were performed to investigate these affects.  
 
4.2.2.1 Endpoint cell counts of HSC-T6 after 48 hrs of culture 
 
To investigate possible differences in the rate of proliferation on different ECM 
surfaces, cell number was quantified 48hrs post seeding. Number of cells on laminin 
was significantly reduced when compared with the non-coated control, whilst cell 
number on gelatin was significantly increased compared with the non-coated control 
(p< 0.05, one-way ANOVA with Tukey’s post-hoc t-test, Figure 4.3). There was a slight 
increase in the number of cells present after 48hrs of culture on collagen I compared 
with those on non-coated plastic; however this is was not statistically significant. Other 
ECM proteins have no statistically significant effects on HSC-T6 cell number compared 
with culture on non-coated plastic; collagen I accumulates in the liver during fibrosis 
and becomes the predominant protein in ECM composition (Bedossa and Paradis, 
2003, Friedman, 2008a). On activation, HSCs produce and deposit collagen I into the 
ECM and are the primary source of ECM deposition in liver fibrosis (Gabele et al., 2003, 
Friedman, 2008b). For this reason, collagen I and laminin were chosen for further 
investigation into their effects on HSCs.
E F 
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Figure 4.3: Mean (+/- SEM) number of HSC-T6 cells on different ECM proteins. * denotes significantly different 
from non-coated control at p<0.05 according to one-way ANOVA with Tukey’s post-hoc t-test. Cells were seeded at 
100,000 cells/ml and counted on a haemocytometer 48 hrs post seeding; three independent repeats were 
conducted and cell number averaged across the repeats. Cell density is expressed as cells per T25 flask.
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A time course of cell number was conducted over 48hrs (Figure 4.4). At no time point 
was cell number significantly different on collagen I compared with non-coated plastic. 
However cell number on collagen I is consistently higher across all time points 
measured up to passage at 48hrs. This may be due to cells attaching faster on collagen 
I than on non-coated plastic and therefore entering the cell cycle earlier (faster 
attachment observed but not quantified). 
 
4.2.2.2 Cell-IQ analysis of HSC-T6 proliferation  
 
To investigate in more detail the effect of collagen I and laminin on proliferation of 
HSC-T6 cells, proliferation was quantified in real-time by Cell-IQ analysis. Cells were 
cultured in the Cell-IQ over 72 hrs, a video of the time course can be viewed on the 
attached CD (see appendix 2). A curve of estimated cell number per well was 
generated using the mean cell counts estimated by the Cell-IQ analysis software at 5 hr 
intervals up to 70 hrs of culture. As can been seen from Figure 4.5, both collagen I and 
laminin have a marked effect on proliferation in HSC-T6 cells compared with 
proliferation on non-coated plastic. Collagen I promotes proliferation, whereas laminin 
inhibits it. Statistical analysis showed that there was no significant difference in initial 
cell density at 0 hrs (p > 0.1 One-Way ANOVA). After 5 hrs in culture, the number of 
cells on laminin is already is already significantly reduced compared with collagen I and 
non-coated plastic (p < 0.01 One-War ANOVA). By 15 hrs in culture, cells cultured cell 
count on collagen I is significantly greater than cell number on non-coated plastic, 
which is also significantly greater than the numbers on cells on laminin (p < 0.01 One-
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Way ANOVA). This trend of altered growth is maintained and at 25 hrs cell number on 
collagen I remains significantly higher (p < 0.01 One-Way ANOVA) than cell numbers 
laminin and non-coated plastic, though cell counts on laminin and non-coated plastic 
no longer differ statistically. Cell numbers on collagen I remain significantly different 
according to One-Way ANOVA (p <0.01) from cell number on non-coated plastic and 
laminin up to hour 45 of culture, and reach plateau at 40 hrs. Cell numbers on laminin 
are significantly fewer at 45 hrs of culture than those on non-coated plastic or collagen 
I (p < 0.01), but cell counts on collagen I and non-coated plastic do not significantly 
differ. By 55 hrs of culture cell growth has plateaued on all surfaces and there is no 
statistically significant difference between cell numbers on any surface. 
 
4.2.3 The morphology of human LX-2 cells and rat primary HSC is not affected ECM 
  
To further study the role of ECM on stellate cell behaviour the effects of ECM on 
another stellate cell line, LX-2, which are derived from human HSC were cultured on 
collagen I and laminin, as these proteins were the substrate that had the most marked 
effect on HSC-T6 cells. Images taken 48 hrs post seeding show no visible effect of 
collagen I or laminin on LX-2 cells attachment or morphology, LX-2 proliferation on 
laminin was slightly reduced, though this effect is not as marked as in HSC-T6 cells 
(Figure 4.6). 
Rat primary HSC cells were also cultured on collagen I and laminin, to investigate any 
effects of these proteins on primary HSCs. Images taken 24 hrs post seeding show no 
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effect of collagen I or laminin effect on primary rat HSCs cells attachment or 
morphology (Figure 4.7, similar to the observations of culture on laminin and collagen I 
on LX-2s (Figure 4.6). 
 
4.2.4 Different ECM proteins do not significantly affect the proliferation of LX-2 cells 
at passage end point, but proliferation is affected by laminin over a passage 
 
Observation of LX-2s in culture on different ECM substrates indicated that proliferation 
might be affected by culture on laminin (Figure 4.6), therefore, end point cell counts 
and Cell-IQ analysis were performed to investigate this affect.  
 
4.2.4.1 End point cell counts of LX-2s after 48 hrs of culture  
 
Cell counts per flask were conducted at 48 hrs post seeding, as previously described for 
HSC-T6 cells, to investigate cell growth on these substrates. No significant difference 
was observed in the proliferation of LX-2s on non-coated plastic, collagen I and laminin 
(Figure 4.8), but cell number on laminin does appear reduced compared with collagen I 
and non-coated plastic, in line with observations made in culture (Figure 4.7).
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Figure 4.4: Affect of ECM on HSC-T6 cell number per T25 across a passage (48 hr). Cells from the same population 
were seeded at 100,000 cells/ml , 5ml per flask and grown on non-coated and collagen I coated flasks. Cells were 
counted on a haemocytometer at four different time points, three independent repeats were conducted and cell 
number averaged across the repeats (+/- SEM). N=3. Not significant (one – way ANOVA p = 0.34). N=3 
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Figure 4.5: Estimated cell number per well across 70 hrs for HSC-T6s cultured on non-coated plastic, collagen I and 
laminin. Cells from the same population were seeded at 100,000 cells/ml, 1 ml per well and grown on non-coated 
plastic, laminin on collagen I. Cell number was estimated by the Cell-IQ analysis software. Cell number on laminin is 
significantly different (p <0.01 one-way ANOVA) from cell number on non-coated plastic or on collagen I between 5-
45 hrs hours of culture, with the exception of hour 25. Number of cells on collagen I are significantly different from 
cell number on non-coated plastic between 15 hrs and 40 hrs. Mean +/- SEM, N=3. 
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Figure 4.6: LX-2 cell morphology on different ECM proteins. Cells were seeded at 300,000 cells/ml imaged 48 hrs 
post seeding at 100x magnification. A) Non-coated. B) Collagen I. C) Laminin. 
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Figure 4.7: Primary rat HSC cell morphology on different ECM proteins. Cells were seeded at 100,000 cells/ml and 
imaged 48 hrs post seeding at 400x magnification. A) Non-coated. B) Collagen I. C) Laminin. 
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Figure 4.8 Mean number (+/- SEM) of LX-2 cells seeded at 300,000 cells/ml on different ECM proteins counted on 
a haemocytometer taken at 48hrs post seeding, N=3. Cell density is expressed as cells per T25 flask
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4.2.4.2 Cell-IQ analysis of LX-2 proliferation. 
 
To investigate the effects of collagen I and laminin on LX-2 proliferation in more detail, 
Cell-IQ analysis was undertaken. Cells were cultured in the Cell-IQ over 72 hrs but cell 
number reached plateau at 40 hrs. A video of the time course can be viewed on the 
attached CD (appendix 3). As can been seen from Figure 4.9, laminin has a marked 
effect on proliferation in LX-2 cells compared with proliferation on non-coated plastic 
and collagen I. There was no significant difference in seeded cell density (p > 0.05 one-
way ANOVA), by 5 hrs of culture cell number on laminin is significantly lower than cell 
number on collagen (p < 0.05 One-Way ANOVA); however there in no difference 
between cell number on non-coated plastic and cell number on either laminin or 
collagen I. At 10 hrs after seeding, cell number on laminin is significantly reduced 
compared with both cell counts on non-coated plastic and collagen I (p < 0.01 One-
Way ANOVA), but there is no difference between the number of cells on non-coated 
plastic and collagen I. This trend in reduced cell number is maintained over 20hrs in 
culture, but there is no significant difference in cell number by 35hrs after seeding (p > 
0.05 one-way ANOVA).
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Figure 4.9: Estimated cell number per well across 45 hrs for LX-2s cultured on non-coated plastic, collagen I and 
laminin. Cells from the same population were seeded at 300,000 cells/ml, 1 ml per well and grown on non-coated 
plastic, laminin on collagen I. Cell number was estimated by the Cell-IQ analysis software. Cell number on laminin is 
significantly different (p <0.01 one-way ANOVA) from cell number collagen I between 5-35 hrs hours of culture and 
non-coated plastic between 10-35 hrs, with the exception of hour 20. 
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4.2.5 Culture on laminin increases ATRA uptake in HSC-T6 cells and LX-2 cells 
 
HSC-T6 cells grown on laminin do not have the typical elongated shape of activated 
HSCs. In contrast they appear rounded and lack projections. Their morphology on 
laminin might be indicative of a quiescent phenotype. A feature of quiescent HSC is 
their capacity to store vitamin A as lipid droplets in the cytoplasm, this is an ability they 
lose on activation (Burmester et al., 2002, Fordel et al., 2004) (discussed section 
1.2.1.2). To investigate whether HSCs cultured on laminin or collagen I have the 
vitamin A storing capacity of quiescent HSCs, HSC-T6 and LX-2 cells were treated with 
ATRA, a metabolite of vitamin A, and uptake was assessed by confocal microscopy. The 
effect of culturing HSC-T6 and LX-2 cells in the presence of 1µM ATRA when grown on 
collagen I, laminin and glass is shown in Figure 4.11 and 4.12, respectively. Figure 4.11- 
E and F and 4.12 – D and E show increased auto-fluorescence of both HSC cell lines 
cultured on laminin in the presence of ATRA when compared with those cultured on 
glass or collagen I in the presence in ATRA (Figure 4.10- A toK). This observation 
indicates that HCS-T6s and LX-2s take up ATRA more readily from the extracellular 
environment when they are cultured on laminin, which is supportive of the hypothesis 
that both these cells have a more quiescent phenotype, compared with those cells 
cultured on collagen I and glass.
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Figure 4.10: A-F) Confocal images of HSC-T6 cells seeded at 100,000 cells/ml on Glass, collagen I and laminin 
coverslips 48hrs post seeding, looking at retinoid auto-fluorescence activated at 351nm and detected at 515nm. A) 
glass, B) glass zoom, C) collagen I, D) collagen I zoom, E) laminin, F) laminin zoom. G-K) Confocal Images of LX-2 cells 
treated with ATRA cultured on glass, collagen I and laminin 48hrs post seeding at 300,000 cells/ml, looking at 
retinoid auto-fluorescence activated at 351nm and detected at 515nm. A) glass, B) collagen I, C) collagen I zoom, D) 
laminin, E) laminin zoom.
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4.3 Discussion 
 
The observations of this study show that different ECM matrices can influence the 
phenotype and behaviour of HSC-T6 and LX-2 cells. Laminin has a most marked effect 
on the morphology of HSC-T6s, with cells not showing the typical elongate shape seen 
on other substrates; however no morphological differences were seen in LX-2s or 
primary rat HSCs on any ECM matrix. Cellular response to ECM is determined by 
membrane receptors in HSCs, therefore, this observation suggests that HSC-T6s might 
have different membrane receptor expression, or differences in their downstream 
signalling cascades, in response to ECM from both LX-2s, which are derived from 
human HSCs, and primary rat HSCs. As the HSC-T6 cell line is derived from rat primary 
HSCs (Vogel et al., 2000), it is unlikely that the difference in morphology in response to 
culture on laminin is due to species differences between rat and human HSCs. Collagen 
I alone, although a major constituent of the hepatic scar, seems to have no effect on 
morphology in HSC-T6s, LX-2s or primary rat HSCs. The mixed collagen I – laminin 
matrices affect the morphology of HSC-T6 cells, with increasing concentrations of 
laminin, and decreasing concentrations of collagen I having an observable effect on cell 
shape. However, collagen I seems to exert a dominant effect, as even at its lower 
concentrations, more cells exhibit an elongate rather than rounded shape. 
Cell proliferation of both HSC-T6 and LX-2 cell lines is affected by ECM; however the 
response of each cell line is different. Both collagen I and laminin affect cell 
proliferation in HSC-T6s compared with the proliferation observed on non-coated 
plastic, with increased proliferation and faster time to confluence observed on 
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collagen I compared with culture on non-coated plastic and laminin. Laminin, on the 
other hand, suppresses proliferation in HSC-T6 cells initially. Laminin also reduces 
proliferation in LX-2 cells, with these cells reaching confluence slower than LX-2s 
grown on non-coated plastic or collagen I. However, interestingly collagen I does not 
increase cell proliferation compared with non-coated plastic in LX-2s, in contrast to the 
observations of the effect of collagen I on cell proliferation in HSC-T6 cells. This 
difference could be due to differences in receptor expression between cell lines, or be 
attributable to the basal activation state of the immortalised cell lines – HSC-T6 cells 
can be described as being semi-activated as they express αSMA, glial acidic fibrillary 
protein and vimentin, which are markers of activation, but they also show retinoid-
related parameters similar to those of freshly isolated quiescent rat HSC including 
expression of all six nuclear retinoid receptors (Vogel et al., 2000). LX-2s have an 
activated phenotype, they express αSMA, βPDGF Receptor subunit, which is not 
expressed by quiescent HSCs and proliferate in response to stimulation with BB-PDGF 
(Xu et al., 2005). The observation that laminin suppresses proliferation in both HSC cell 
lines is in contrast to the different response of these cell type in terms of their 
morphology on this substrate, but might indicate that different signalling mechanisms 
are involved in the morphological and proliferative responses. Further evidence of 
matrix effects on phenotype is seen in HSC-T6 and LX-2 cells ability to take – up ATRA. 
Cells cultured on laminin show increased ability to store ATRA in the form of retinoids 
compared with those grown on collagen I or glass. ATRA has been shown to modulate 
primary rat HSC phenotype, reducing the production of collagen I and III and also 
fibronectin and reduced proliferation (Goodman et al., 1987). Interestingly, the effect 
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of laminin on ATRA up – take appears to be the same in both cell lines, in spite of the 
differences between HSC-T6s and LX-2s in terms of morphology and proliferation, on 
these substrates.  
ECM effects on HSCs have been previously documented (Friedman, 2008b), Friedman 
et al. (1989) reported that basement membrane matrix maintained a differentiated 
phenotype in primary rat HSCs in culture. HSCs were cultured on EHS, comprising 
approximately 90% laminin, 6% collagen type IV and 4% heparin sulfate proteoglycan, 
and, therefore, approximated ECM in a normal liver. ESH was found to affect cell 
morphology and reduce collagen synthesis and proliferation. Gaҫa et al.(2003), found 
that Matrigel, a basement-membrane type coating containing collagen IV and laminin, 
reduced primary rat HSC proliferation, collagen synthesis and expression of markers of 
activation such as αSMA, but collagen IV and laminin alone did not produce a 
reduction in marker expression. These observations are in-line with the results 
presented in the current study, where cultures of HSC-T6s on laminin, a major 
constituent of the basement matrix in a normal liver, appear rounded, and 
proliferation of HSC-T6s and LX-2s is reduced when cultured on laminin. Collagen I has 
been reported to support and activated phenotype in HSC, Davis (1988) observed that 
primary HSC cultured on collagen I showed increased responsiveness to stimulation 
with TGF-β, with greater accumulation of collagen I and collagen III. Collagen I has also 
been shown to enhance migration in HSC-T6s and LX-2s (Yang et al., 2008), however, 
unlike the results presented here, collagen I did not alter proliferation. This difference 
between the results reported here and the observations of Yang et al. (2008) might be 
due to this group only performing end point analysis of HSC proliferation, and not a 
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time course as is presented here. End point analysis shows no significant difference in 
cell number after 48hrs of culture in LX-2s or HSC-T6s for this study either, but time 
course analysis shows differences in proliferation across the culture period.  
Davis et al. (1990) have shown that retinol and retinoic acid also have an impact on the 
behaviour of primary rat HSCs. Treatment with retinol and retinoic acid inhibited cell 
proliferation, with retinoic acid having a more potent effect. Retinoic acid also reduced 
interstitial collagen and TGF-β production in these cells, implying these cells were 
exhibiting a more quiescent phenotype. Demonstrated here is the effect that ECM 
culture substrate can have on the ability of HSC-T6s and LX-2s to take up ATRA and 
store retinoids, a feature of quiescent HSCs, where collagen does not increase ATRA 
uptake, but laminin has a marked effect. 
The effect of culture on gelatin (denatured collagen) on HSC proliferation was a 
surprising result, and was marked, new research into fibrosis resolution and matrix 
degradation suggests that HSC may come into contact with a form of denatured 
collagen during the resolution process, which might be similar in structure to gelatin 
(Friedman, 2008c, Ramachandran and Iredale, 2012). The reasons for this increased 
proliferation are unknown and were not explored within this study. It might be that 
increased exposure of binding sites caused by denaturation is causing increased 
signalling and subsequent cell proliferation, but further work would be required to 
confirm whether an increase in signalling is the cause of the increase in proliferation. 
The results of this study are consistent with those that have been previously reported, 
namely that HSC culture on different ECM substrates effects cell behaviour and 
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phenotype. Specifically culture on a substrate that resembles the basement membrane 
matrix of a normal liver confers a more quiescent phenotype on HSCs, and culture on a 
substrate resembling the collagen I rich hepatic scar that develops on liver injury gives 
a more activated phenotype. Cygb has been implicated in the activation of HSCs as is 
discussed in Chapter 1, sections 1.1.8.2 and 1.2.1.4; however the influence of ECM on 
Cygb expression has not been investigated. As it is clear that ECM can affect HSC 
phenotype, it is feasible that modulation of Cygb expression could also be influenced 
via the ECM signalling pathway. The effect of ECM culture substrate on Cygb 
expression is investigated in Chapter 5. 
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Chapter 5 
Regulation of Cygb 
by ECM 
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5.1 Introduction 
Results presented in Chapter 4, demonstrate that ECM components can influence HSC 
morphology, and also phenotype in terms of the ability of HSC to take up ATRA, 
suggesting differences in HSC activation state. What is not yet known is if these effects 
extend to regulation of Cygb expression, which has been reported to be upregulated in 
HSCs in a fibrotic liver (Kristensen et al., 2000, Kawada et al., 2001). Changes in Cygb 
expression in these HSCs during fibrogenesis could be important to cell function (for 
example collagen synthesis and deposition). ECM signalling has been shown to 
influence behaviour and gene expression in HSCs (see section 4.3); therefore basement 
substrate might also influence Cygb expression. This study aims to characterise Cygb 
gene expression in HSCs cultured on different ECM substrates and to investigate 
possible signalling mechanisms linking ECM to Cygb expression. 
 
5.2 Results 
5.2.1 ECM proteins affect the expression of Cygb and αSMA  
 
RT-PCR was undertaken on RNA extracted from HSC-T6 cells at the end of three 
passages. Cygb expression was investigated and αSMA was chosen as early stage 
marker of stellate cell activation (Friedman, 2008b). Figure 5.1 shows a significant 
increase in αSMA expression on collagen I, collagen IV, fibronectin and gelatin, 
whereas expression is significantly decreased on laminin (Fold changes in log base 2: 
1.4, 0.7, 0.6, 1.1 and -0.6, respectively). Therefore, activation status of HSC-T6 cells 
according to αSMA mRNA (messenger RNA) expression was significantly affected by all 
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of the ECM proteins tested when compared with expression on non-coated tissue 
culture treated plastic (p < 0.05 one-way ANOVA with Tukey’s Post-Hoc or t-test 
assuming equal variances). 
RT-PCR analysis of Cygb mRNA expression showed that ECM proteins also changed 
expression of Cygb in the HSC-T6 line. Three of the ECM proteins tested showed 
significant differences in expression when compared with Cygb expression in HSC-T6 
cells cultured on a non-coated surface. HSC-T6 cells cultured on laminin show a 
significant increase in Cygb expression (p<0.05, one-way ANOVA with Tukey’s post-
hoc, fold change [log base 2] 1.0), in contrast to those grown on collagen I (p<0.05 t-
test, fold change [log base 2] -0.6) or gelatin (p<0.05 one-way ANOVA with Tukey’s 
post-hoc, fold change [log base 2] -0.9), which show a decrease in expression when 
compared with expression in cells cultured on a non-coated control. Interestingly, 
change in expression of Cygb on all three of these coatings was reciprocal to the 
expression of αSMA. The upregulation of Cygb in HSC-T6 cells on laminin compared 
with collagen I and non-coated plastic was also confirmed by western blot at the 
protein level (Figure 5.2). 
To confirm that this effect was not specific to HSC-T6 cells the effect of collagen I and 
laminin on CYGB expression was also interrogated in LX-2 cells. Figure 5.3 shows that in 
LX-2 cells, culture on collagen significantly decreases (p=0.05, Kruskal Wallace, fold 
change [log base 2] -1.9) CYGB mRNA levels compared with non-coated plastic, in line 
with the observations of the effect of collagen I on CYGB expression in HSC-T6 cells. 
However, unlike HSC-T6 cells, laminin has no effect on CYGB expression in LX-2 cells. 
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5.2.2 Time dependant expression of Cygb on collagen I 
 
To explore Cygb expression on collagen I and non-coated plastic in more detail, RNA 
was extracted from HSC-T6 cells cultured on non-coated plastic and collagen I at four 
time points across a passage and compared with RNA extracted from cells grown to 
confluence on a non-coated tissue culture surface. Figure 5.4 shows that Cygb mRNA 
expression changes in a time dependent manner on both surfaces, with expression 
decreasing at lower cell densities. At 48 hrs Cygb mRNA expression remains repressed 
in cells cultured on collagen I, whereas on non-coated plastic Cygb mRNA levels return 
to levels comparable with the control RNA extractions from a confluent non-coated 
flask, there is only a significant difference between Cygb mRNA expression in cells 
cultured on collagen I compared with cells grown on non-coated plastic at 48hrs after 
seeding (p<0.05 Mann-Whitney fold change [log base 2] non-coated – 0.4, collagen I 
coated – 1.1) 
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Figure 5.1: Mean (+/- SEM) expression of Cygb and αSMA in HSC-T6 cells cultured on different ECM proteins 
analysed by RT-qPCR calibrated to expression on non-coated flasks. * denotes significance at p<0.05 according to 
one-way ANOVA with Tukey’s post-hoc t-test, + denotes significance at p<0.05 according to t-test assuming equal 
variances when compared with expression on the non-coated control. N=3 
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Figure 5.2: Expression of Cygb in HSC-T6 cells cultured on laminin, collagen I and non-coated plastic analysed by 
western blot. 
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Figure 5.3: Mean expression (+/- SEM) expression of CYGB in LX-2 cells cultured on collagen I and laminin proteins 
analysed by RT-qPCR calibrated to expression on non-coated flasks. * denotes significance at p=0.05 according to 
Kruskal Wallace compared with expression on a non-coated control. N=3.
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Figure 5.4: Mean (+/- SEM) expression of Cygb across a passage (48hr) on non-coated and collagen I coated flasks 
relative to 0hr time point on a confluent non-coated plastic. * denotes significance at p<0.05 compared with 
expression on non-coated plastic according to Mann-Whitney test. N=3.
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5.2.3 Surface coated collagen is required for regulation of Cygb 
 
The effects of the presence of collagen I on HSC-T6 cells were explored via response to 
different concentrations of collagen I either in solution in the media or coated onto a 
plate to investigate whether attachment to a collagen surface is required for regulation 
of Cygb. Figure 5.5 A and B indicate that cell attachment to collagen coated surfaces is 
necessary for an effect on Cygb expression to be observed. There was no effect of 
collagen I when diluted into the media on Cygb expression (Figure 5.5 A). When 
compared with cells cultured on commercial collagen I coated flasks (BD Biocoat®), 
Cygb was downregulated on the coated surface compared with all concentrations of 
collagen I in the media. Figure 5.5 B demonstrates that concentrations of collagen I 
greater than 6 and 10 µg/cm2 coated on to the culture surface have an increased effect 
on Cygb expression in HSC-T6 cells. Significant down regulation (p<0.05 one-way 
ANOVA with Tukey’s post-hoc) of Cygb was observed in cells cultured on 0.4, 6 and 10 
µg/cm2 collagen I when compared with expression in cells cultured on non-coated 
plastic (fold change [log base 2] -0.3, -0.6 and -0.6, respectively) and there was 
downregulation of Cygb expression at all concentrations of collagen I when cells are 
grown on the matrix.
120 
 
 
 
Figure 5.5: Mean (+/- SEM) expression of Cygb in HSC-T6 in the presence of collagen I 48 hrs after seeding. A) Cygb 
expression in cells cultured on non-coated plastic with collagen I diluted into the culture media relative to Cygb 
expression on non-coated plastic. B) Mean (+/- SEM) Cygb expression in cells cultured on collagen I coated plates at 
different concentration relative to Cygb expression on non-coated plastic. ** denotes significant difference (p 
<0.01) from non-coated control according to one-way ANOVA with Tukey’s post-hoc t test. Three repeats were 
conducted and relative expression averaged across the repeats. Positive control is a commercially bought collagen I 
coated plate from BD BioCoat®
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5.2.4 Intracellular ROS in HSC-T6s cultured on collagen I, laminin and non-coated 
plastic 
 
CYGB has been implicated in ROS scavenging (see section 1.1.6.2), and as Cygb 
expression was altered in HSC-T6 cells cultured on collagen I and laminin, levels of 
intracellular ROS were investigated in these cells (Figure 5.6). Although not statistically 
significant (p > 0.05, Kruskal-Wallace), the trend expected from the differences in Cygb 
is observed. Intracellular ROS is increased in HSC-T6 cells cultured on collagen I, where 
Cygb is downregulated, in line with the increase in intracellular ROS in the H2O2 treated 
positive control. Levels of intracellular ROS in cells cultured on laminin appear to be in 
line with cells cultured on non-coated plastic, and lower than ROS in the positive 
control cells or those cultured on collagen I.
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Figure 5.6: Mean (+/- SEM) relative levels of intracellular ROS in HSC-T6 cells cultured on non-coated plastic, 
collagen I laminin and cells treated with 20µM H2O2 for 1hr prior to analysis by fluorescence of H2DCF-DA by flow 
cytometry. N=3.
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5.3 Discussion 
 
As well as effecting cell morphology as described in Chapter 4, different ECM proteins 
also regulate the expression of Cygb and stellate cell activation as assessed by αSMA 
expression. Work in this chapter has shown that HSC-T6s cultured on collagen I, 
collagen IV, fibronectin and gelatin, had an increased activation state as measured by 
αSMA. HSC-T6 cultured on laminin had decreased αSMA expression compared with 
expression on non-coated plastic, indicating a more quiescent phenotype. Therefore all 
ECM substrates had a significant effect on αSMA expression. It has been reported that 
far from acting simply as a mechanical cell scaffold, the ECM has an active role in 
modulation of cell behaviour (Martinez-Hernandez and Amenta, 1995). ECM proteins 
have various biological functions due to their ability to interact with other molecules 
such as other ECM proteins, cytokines and growth factors, signalling receptors and 
adhesion molecules. These functions are mediated by the specific domains present 
within each protein (Kim et al., 2011). Cells such as HSCs also contribute to ECM 
remodelling and alter the balance of ECM proteins surrounding them, in turn changing 
the signals they receive (Wight and Potter-Perigo, 2011).  
The ECM provides signals that help determine gene expression and cell fate of all cells 
(Streuli, 2009). The effect a variety of ECM proteins on HSC behaviour have been 
previously documented and are discussed in section 4.3. Work presented in this 
chapter demonstrates that modulation of the expression of activation markers and 
Cygb by ECM matrix, specifically collagen I in an HSC cell culture model. There is 
increasing research into fibrosis resolution and matrix degradation (Friedman, 2008c, 
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Ramachandran and Iredale, 2012), it is hypothesised that HSC may come into contact 
with a form of denatured collagen during the resolution process, which may be similar 
in structure to gelatin. In support of this hypothesis this study demonstrated that 
gelatin had a marked effect on activation state (αSMA expression), Cygb expression 
and proliferation of HSC-T6 cells, though the mechanism of action remains to be 
determined. 
To our knowledge there have been no studies into whether ECM proteins affect the 
expression of Cygb in HSCs, this study has shown that RNA expression of Cygb is 
altered by culture matrix and that this is dependent on attachment to the matrix in the 
case of collagen I. The results presented here suggest that ECM proteins may signal to 
regulate Cygb gene expression within HSC, and the possible pathway involved is 
investigated in Chapter 6 
Interestingly and unexpectedly, Cygb expression on collagen I was downregulated 
compared with expression on non-coated plastic, and a more marked but similar result 
was observed in HSC-T6s cultured on gelatin, whereas the opposite effect was seen in 
HSC-T6s grown on laminin. Although the observation that Cygb is downregulated on 
collagen I was unexpected in the context of the HSC activation, there is some support 
for the observation that Cygb RNA is downregulated by collagen I in vivo. Mann et al. 
(2008) reported an increase in Cygb RNA expression in CCl4 treated mouse liver at 
24hr, which was followed by an increase in collagen IαI expression at 48hr,however 
the 48hr time point, where collagen IαI is increased, Cygb RNA expression had 
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significantly decreased, to below that of normal liver levels, suggesting that collagen I 
deposition in a fibrotic liver could result in a reduction in Cygb. 
Evidence suggesting that Cygb may be downregulated in fibrosis has also been 
reported by Cui et al. (2012), who reported that primary HSCs treated with arundic 
acid showed a marked increase in Cygb RNA and protein expression, associated with a 
decrease in αSMA RNA and protein expression, suggesting a more quiescent 
phenotype. Le et al.(2012) also presented evidence that Cygb may be anti-fibrotic, 
where Cygb knock-out mice showed increased hepatosteatosis when fed a choline-
deficient amino-acid defined diet. These reports agree with our in vitro observations of 
HSC-T6 activation state and Cygb RNA expression. Western blot analysis of Cygb 
protein expression on laminin, collagen I and non-coated plastic confirmed the 
observation from RT-PCR, that Cygb expression is increased on laminin. Surprisingly, 
the indicated mass of the protein bands on the western blot were much larger than 
the reported weight of Cygb (21 kDa) at between 70-100 kDa. However, recent 
research by Tsujino et al. (2014) has shown that wild type CYGB can exist as a tetramer 
with two bands visible at approximately 75-80 kDa. Therefore, it seems plausible that 
CYGB exists in the tetrameric form in HSCs, and this may be related to its function in 
these cells as CYGB ligand binding affinity is affected by polymerization, each state 
showing different binding affinities for cyanide, with the monomer having the highest 
affinity, and in the ferrous state, affinities for CO also differ (Tsujino et al., 2014). 
Furthermore, collagen I had the same suppressive effect on CYGB expression -LX-2 
cells, but, unlike in HSC-T6s, laminin has no effect on CYGB expression this cell line, as 
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discussed in Chapter 4, this could be indicative of differences between the HSC-T6 and 
LX-2 cell lines. These differences could be due to differences in receptor expression, 
artefacts of cell immortalisation or species differences; further investigation is needed 
to elucidate the cause of the difference. Observation of the suppressive effect of 
collagen I on Cygb expression in both cell lines suggests that this is not specific to HSC-
T6 cells and could therefore be related to true stellate cell biology.  
Results showed that on both collagen I and non-coated plastic, Cygb expression is 
changed in a time dependant manner, with expression initially decreasing and 
remaining suppressed over 48hrs on collagen I but returning to initial levels on non-
coated plastic, suggesting a signalling mechanism between collagen I and Cygb 
expression. The effects of collagen I on Cygb expression show that attachment of the 
cells to a basement matrix is required, and these effects are greater at higher 
concentrations of collagen I, again indicating a signalling through surface membrane 
receptors and the existence of ‘outside-in signalling’ between the ECM and Cygb gene 
regulation, whereby ECM composition effects Cygb RNA expression in both the HSC-T6 
and LX-2 cell lines. Taken in context this may be important in the fibrotic process and 
the development of liver disease. Adherent cells require attachment to the ECM to 
advance through the cell cycle, changes in ECM composition on injury to the liver 
initiate positive and negative feedback pathways to regulate fibrosis. Primary amongst 
these changes are modifications in cell surface receptors, particularly integrins 
(Friedman, 2008b, Streuli, 2009). Activation of these receptors results in the formation 
of focal adhesions leading to a down-stream signalling cascade. HSCs have been shown 
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to express many ECM protein receptors, including several integrins and both discoidin 
domain receptors (Leitinger and Hohenester, 2007, Friedman, 2008c, Patsenker and 
Stickel, 2011). In Chapter 6 signalling from the ECM to Cygb in HSCs is investigated. 
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Chapter 6 
Signalling between 
ECM and Cygb 
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6.1 Introduction 
 
Changes in ECM composition in the process of liver fibrosis are discussed in sections 
1.2.3 and 1.2.4. These changes drive alterations in membrane receptors in HSC, 
particularly integrins, indicating the ECMs’ role not only as a scaffold but as part of the 
cell-cell communication network via cell surface receptors (Benyon and Iredale, 2000, 
Bedossa and Paradis, 2003, Friedman, 2008c). An exhaustive review of integrin 
signalling is beyond the scope of this thesis; however a short overview of integrins, 
outside-in signalling and the downstream signalling cascades initiated from integrin 
activation are important for the context of this research. Integrins are transmembrane 
protein receptors, which mediate interactions between cells and their surrounding 
environment (Humphries, 2000, Patsenker and Stickel, 2011). Intercellular binding to 
ECM via integrins is one of the major influences on cell behaviour (Streuli, 2009). They 
were originally termed ‘integrin’ for their ability to integrate intracellular and 
extracellular responses (Hynes, 1987). Binding to ECM initiates the transmission of 
internal cell signals, termed ‘outside-in signalling’ and can provide instructions for gene 
expression (Clark and Brugge, 1995, Qin et al., 2004, Streuli, 2009). HSC have been 
shown to express many cell surface receptors for ECM proteins including integrin 
subunits, which recognise many different ECM protein ligands and are discussed in 
section 6.1.3. 
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6.1.1 The structure of integrins 
 
Integrins are non-covalently associated heterodimers composed of a large extracellular 
domain (700 – 1100 residues) and a short cytoplasmic domain (30 – 50 residues). The 
dimers are formed by the association of an α subunit of approximately 180 kDa and a β 
subunit of approximately 95 kDa, both of which are type I membrane glycoproteins. 
The extracellular domain of the integrin heterodimer comprises an asymmetric 
structure, formed of a globular ‘head’ on two flexible ‘legs’. To date 18 α subunits and 
8 β subunits, forming 24 heterodimers have been reported (Humphries, 2000, Arnaout, 
2002, Stupack, 2007). Figure 6.1 illustrates the basic structure of an integrin.  
 
6.1.2 Integrins, focal adhesions and focal adhesion kinase (FAK) 
 
On activation, such as binding to ECM proteins, integrins cluster on the membrane 
plane, form focal adhesions and recruit non-receptor tyrosine kinase signalling 
molecules like focal adhesion kinase (FAK), which is one of several components that 
make up the focal adhesion, (Leitinger and Hohenester, 2007, Desgrosellier and 
Cheresh, 2010). On binding to an activated integrin, FAK itself becomes activated and 
autophosphorylates at tyrosine (Y) 397. Tyrosine phosphorylation is a key event in the 
formation of focal adhesions and FAK is a major signalling factor within them. 
Autophosphorylation of FAK Y397, which has been shown to be important in many of 
FAKs functions, initiates further phosphorylation events leading to an intracellular 
signalling cascade, Figure 6.2 depicts integrin clustering and focal adhesion formation, 
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leading to FAK phosphorylation and downstream intracellular signalling. FAK has been 
shown to be involved in cell migration and proliferation (Cary and Guan, 1999 
Wozniak, 2004 ). 
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Figure 6.1: A simplified schematic of the structure of an integrin heterodimer showing the 
transmembrane region, the α and β subunits and the globular ‘head’ and flexible ‘legs’. 
 
 
 
 
 
 
 
 
‘Head’ 
‘Legs’ 
133 
 
 
 
 
 
Figure 6.2: A simplified schematic of integrin clustering, focal adhesion formation and FAK 
autophosphorylation leading to downstream signalling.
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6.1.3 Integrins associated with HSC 
 
Table 6.1 gives summary detail of integrin subunits known to be expressed by HSCs. 
Table 6.1: Integrin subunits associated with HSCs. References: Leitinger and Hohenester(2007), Friedman (2008b) 
and Patsenker and Stickel, (2011) 
Receptor Subunit Structure and Combinations Ligands 
Integrin beta 1 (β1) Forms heterodimers with 
integrin alpha subunits. In this 
instance, expression with 
regard to α11 and α2 is the 
focus. 
When associated with α11, 
preferentially fibril forming 
collagens with specific sites 
for collagen I identified.  
 
When associated with α2, 
preferentially fibril-forming 
collagens, with specific sites 
for collagen I and III 
identified, but also laminin 
and fibronectin. 
 
When associated with α5, 
preferentially fibronectin, 
tenascin and collagens. 
Integrin alpha 11 (α11) Forms a heterodimer with 
integrin β1 subunit. 
See β1 
Integrin alpha 2 (α2) Forms a heterodimer with 
integrin β1 subunit.  
See β1 
Integrin alpha 5 (α5) Forms a heterodimer with 
integrin β1 subunit. 
See β1 
Integrin beta 3 (β3) Forms a heterodimer with 
integrin αv subunit. 
Interacts with collagen, 
fibronectin, vitronectin, 
fibrinogen and tenascin when 
associated with the αv 
integrin subunit.  
Integrin beta 4 (β4) Forms a heterodimer with 
integrin α6 subunit. 
 
Evidence for interactions with 
fibronectin and laminin. Integrin alpha 6 (α6) Forms a heterodimer with 
integrin β4 subunit. 
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Attachment to ECM has been found to influence gene expression though integrin 
signalling (Miranti and Brugge, 2002, Streuli, 2009) and it has been previously reported 
that integrin activation can influence HSC behaviour. Zhou et al. (2004) found that 
antagonising the αV integrin subunit inhibited the proliferation of primary rat HSCs and 
increased apoptosis in these cells. Inhibition of the β1 subunit by a monoclonal 
antibody in human primary HSCs also reduced attachment to laminin, collagen I, 
collagen IV and fibronectin (Carloni et al., 1996). HSCs also show de novo expression of 
α8β1 on activation by CCl4 or bile duct ligation in rats, and upregulation of αvβ3 on in 
vitro activation of rat and human primary HSC (Carloni et al., 1996), suggesting an 
important role for integrins in the fibrotic process. 
HSCs have also been shown to express discoidin domain receptors (DDR), which are 
collagen receptors that are distinct from integrins. DDR1 and DDR2 comprise a 
subfamily of receptor tyrosine kinases that have differing affinities for different 
collagens, DDR1 is activated by both fibrillar and non-fibrillar collagens, whereas DDR2 
is only activated by fibrillar collagens such as collagen I and collagen III (Song et al., 
2011). Collagen I has been shown to stimulate DDR2 phosphorylation in HSC-T6 cells 
and culture on the basement membrane-like substrate matrigel reduced DDR2 
expression in HSC-T6s compared with expression in cells cultured on collagen I. Over-
expression of DDR2 in HSC-T6s also promoted cell proliferation and matrix 
metalloproteinase 2 expression (Olaso et al., 2001). Thus, it is also feasible that DDRs 
could be involved in the changes in Cygb expression, morphology and proliferation 
that have been reported in chapters 3 and 4 of this thesis. The aims of the study 
reported in this chapter were to identify possible mechanisms of signal transduction 
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from ECM to Cygb through cell surface receptors and then downstream through 
intracellular signalling. 
 
6.2 Results 
6.2.1 Cell Surface ECM protein receptors are differently expressed in HSC-T6 cells 
cultured on different ECM proteins 
 
Surface ECM protein receptors are differently expressed in HSC-T6 cells cultured on 
different ECM proteins. To investigate possible pathways for differential Cygb RNA 
expression in HSC-T6 cells, RT-PCR was undertaken on seven receptor sub-units for 
ECM proteins and also DDR1 and DDR2. The receptors screened are detailed in Table 
6.1. The rationale for receptor choice was based on receptors associated with ECM 
proteins effecting the most marked changes in Cygb RNA expression, collagen I, gelatin 
and laminin. 
Figure 6.3 shows RT-PCR results for two of the receptors screened. Of the nine 
screened, these two integrin receptor subunits (α2 and β4), showed significant 
(p<0.05) differences in expression in HSC-T6s cultured on laminin, collagen I and 
gelatin, using receptor expression in cells cultured on non-coated plastic as the 
reference. These differences mirror the differences in Cygb and αSMA expression 
observed on these surfaces. The α2 subunit preferentially binds with fibrillar collagens 
such as collagen I when associated with the β1 subunit. As indicated in Figure 6.3 A, α2 
expression is significantly upregulated in cells cultured on collagen I and gelatin when 
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compared with expression on laminin. The opposite is true for the β4 subunit, shown 
in Figure 6.3 B. This subunit is reported to associate with laminin (see Table 6.1). The 
other seven receptors screened showed no significant changes in expression (see 
appendix 4), except α5, which was significantly down regulated on collagen I (p < 0.05 
one-way ANOVA with Tukey’s post hoc t-test) compared with expression on non-
coated plastic. However α5 showed no statistically significant difference in expression 
on laminin or gelatin (Figure 6.4).  
 
6.2.2 ECM affects FAK phosphorylation in HSC-T6s 
 
In support of a role for ‘outside-in signalling’ by ECM via integrin clustering, focal 
adhesion formation and autophosphorylation of FAK (pFAK) leading to downstream 
signallingwas analysed. Figure 6.5 A-C show that levels of FAK (pY397) protein is 
greater in HSC-T6 cells cultured on collagen I than in those cells cultured on laminin or 
non-coated tissue culture plastic, as assessed by western blot analysis. 
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Figure 6.3: RT-PCR expression of A) α2 (N=5) and B) β4 integrin subunit ECM receptors across laminin, collagen I 
and gelatin ECM proteins in HSC-T6 cells relative to the expression levels of those grown on non-coated T25 
culture flasks. * denotes significance at p< 0.05 according to one-way ANOVA with Tukey’s post hoc t-test, + 
denotes singnificance at p<0.05 according to t-test assuming equal variences, +/- SEM (N=3). 
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Figure 6.4: Expression data for α5 integrin subunit ECM receptor across laminin, collagen I and gelatin ECM 
proteins in HSC-T6 cells relative to the expression levels of those grown on non-coated T25 culture flasks. * 
denotes significance at p< 0.05 according to one-way ANOVA with Tukey’s post hoc t-test, +/- SEM (N=2). 
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Figure 6.5: pFAK expression in HSC-T6 cells cultured on non-coated plastic and collagen I A) Western blot for levels 
of phosphorylated FAK Y397 in cells cultured on laminin, non-coated tissue culture plastic and collagen I with β-
Actin loading control. B) Mean FITC fluorescence +/- SEM (N=3) in HSC-T6 cells cultered on non-coated plastic and 
collagen I, analysed by flow cytometry, p< 0.05 according to one-way ANOVA with Tukey’s post hoc t-test  C) and D) 
Confocal image of cells cultured on glass and collagen I respectively and probed for expression of phosphorylated 
FAK Y397 (N=3). 
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6.2.3 RNAi of FAK was unsuccessful and had no effect on Cygb expression in HSC-T6 cells. 
 
To investigate whether reduction of FAK expression would reconstitute Cygb expression in 
HSC-T6 when cultured on collagen I, RNAi of FAK was undertaken. After initial optimisation 
(appendix 5) RNAi of FAK expression in HSC-T6s cultured on non-coated plastic and collagen 
I was carried out, followed by RT-PCR analysis of both FAK and Cygb expression. As Figure 
6.6 shows, RNAi of FAK only achieved an approximately 25% reduction in FAK expression in 
cells cultured on non-coated plastic (Figure 6.6 A) and no reduction in FAK expression in 
cells cultured collagen I (Figure 6.6 B). Unsurprisingly, there was no effect of FAK RNAi 
treatment on Cygb expression in these cells either, and the non-targeting control RNAi 
treatment (NT2 and NT4), appear to have off-target effects on Cygb expression in cells 
cultured on non-coated plastic (Figure 6.7). 
 
6.2.4 Inhibition of FAK with FAK Inhibitor 14  
 
As an alternative approach to RNAi, to further investigate the effects of FAK 
autophosphorylation and the downstream signalling resulting from this 
autophosphorylation on Cygb expression, inhibition of FAK phosphorylation by FAK Inhibitor 
14 (FAKI) was optimised in HSC-T6 cells. FAKI has been shown to inhibit 
autophosphorylation of FAK Y397 in the BT474 breast cancer cell line (Xu et al., 2005), and, 
therefore, might also inhibit autophosphorylation in HSC-T6s. Initially an MTT test was 
conducted on cells cultured on non-coated tissue culture plastic, with concentrations of FAK 
I between 0 and 100 µM as suggested in the literature (Xu et al., 2005). The second lowest 
concentration of FAK I (10 µM) proved toxic to HSC-T6 cells. Furthermore, the lowest 
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concentration (1µm) caused approximately 30% cell death when initially tested (Figure 6.8 
A). A second MTT assay was conducted with a lower concentration range between 0 and 
1µM on non-coated plastic and collagen I. Figure 6.8 B shows the results of the second MTT 
assay, for cells cultured on collagen I only the highest concentration of FAKI (1 µM) had 
significant effect on cell viability, where as a significant effect was observed for both 0.5 µM 
and 1µM in cells cultured on non-coated plastic.  
Initial western blot analysis was conducted on cells treated for 24 hrs (recommended in the 
literature, Golubovskaya et al.(2008)) and 48 hrs. Although the 24 hr treatment showed a 
good response to FAKI with increasing concentrations inhibiting FAK pY397 expression in 
cells cultured on both surfaces, the 48 hr treatment showed a lack of inhibition, suggesting 
the treatment is unsuitable for 48 hr periods (appendix 6). As previously stated in section 
5.2.2, Cygb RNA expression in HSC-T6 cells cultured on non-coated plastic and collagen I 
differs at the 48hr time point. Thus, it is important that the FAKI treatment is effective at 
this point, to investigate if inhibiting FAK effects Cygb expression in these cells. To this end, 
two treatment regimes were conducted, where HSC-T6 cells were either cultured for 24hrs 
then treated with FAKI for 24hrs, or treated for 24hrs then cultured for a further 24hrs in 
inhibitor-free media. Figure 6.9 shows that FAKI effects FAK Y397 phosphorylation through 
the cultured for 24hr then treated for 24hr regimen by flow cytometry (Figure 6.9 A) and 
confocal microscopy (Figure 6.9 B). A visible decrease in phosphorylated FAK is detected in 
HSC-T6 cells treated with FAK in a concentration dependant manner by both analysis 
methods (Figure 6.9). 
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Figure 6.6: FAK expression after RNAi treatment with PKt2 (FAK) in HSC-T6 cells seeded at 100,000 
cells/ml, cultured for 48 hrs with 24 hrs RNAi on A) non-coated plastic and B) collagen I, then analysed for 
PKt2 expression by RT-PCR. Abbreviations: NT2 = non-targeting siRNA cocktail 2, NT4 = non-targeting siRNA 
cocktail 4. +/- SEM (N=3). 
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Figure 6.7: Cygb expression after RNAi treatment with PKt2 (FAK) in HSC-T6 cells seeded at 100,000 
cells/ml, cultured for 48 hrs with 24 hrs RNAi on A) non-coated plastic and B) collagen I then analysed for 
Cygb expression by RT-PCR. Abbreviations: NT2 = non-targeting siRNA cocktail 2, NT4 = non-targeting siRNA 
cocktail 4. =+/- SEM (N=3). 
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Figure 6.8: Results of MTT viability assay for HSC-T6 treated for 48hrs with FAKI. Cells were seeded at 
100,000 cells/ml and immediately treated with FAKI. MTT assay was undertaken at 48 hrs of culture and cell 
viability normalised to a percentage of the untreated control cells. A) Viability of HSC-T6 cells cultured on 
non-coated plastic and treated with FAKI concentrations between 0 and 100 µM for 48 hrs. B) Viability of 
HSC-T6 cells cultured on non-coated plastic and collagen I and treated with FAKI concentrations between 0 
and 1 µM for 48 hrs. +/- SEM (N=3) 
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Figure 6.9: Results of pFAK inhibition in HSC-T6 cells A) Median (+/- SEM) flouresence of FAK pY397 
analysed by flow cytomtery in cells treated with different concentrations FAKI. Cells were seeded at 100,000 
cells/ml cultured for 24hrs prior to 24hrs of treatment with FAKI then probed for FAK pY397. B) Confocal 
Microscopy of cells probed for FAK pY397 cultured on non-coated (B-1-4) or collagen I coated (B-5-8) 
coverslips. Cells were either untreated (B-1 and B-5) or treated with 0.1µM (B-2 and B-6), 0.5 µM (B-3 and B-
7) or 1.0µM (B-4 and B-8) FAKI 14. 
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6.2.5 The effect of FAKI on Cygb expression is inconclusive 
 
To investigate the effect of blocking FAK autophosphorylation with FAKI on Cygb expression 
in HSC-T6 cells, western blot and RT-PCR analysis of Cygb expression in HSC-T6 cells treated 
for 24 hrs FAKI was undertaken. Figure 6.10 shows the results of these analyses; western 
blot suggests a possible increase in Cygb protein expression in HSC-T6 cells treated with 
FAKI (Figure 6.10 A), where as RT-PCR shows no clear effect and the error bars are large, 
reducing confidence in the result obtained (Figure 6.10 B), there is no statistically significant 
difference between any treatment or from the or negative control. These results give no 
conclusive evidence for or against FAK autophosphorylation being involoved in the signalling 
cascade from ECM to Cygb expression in HSC-T6 cells. 
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Figure 6.10: The effect of pFAK inhibition on Cygb expression in HSC-T6s A) Western blot for Cygb in HSC-
T6 cultured on non-coated plastic or collagen I and treated with different concentrations of focal adhesion 
kinase inhibitor 14 (FAKI) with a β-Actin loading control. B) RT-PCR of HSC-T6 cultured on non-coated plastic 
or collagen I and treated with different concentrations of focal adhesion kinase inhibitor 14 (FAKI), N of at 
least 3 for all treatments.
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6.3 Discussion 
 
This study reports different expression of integrin subunit RNA in HSC-T6 cells cultured 
on laminin, collagen I and gelatin. It has been previously reported that ECM protein 
receptors can be up-regulated upon HSC activation, particularly integrins. For example 
α5β1 integrin expression has been shown to increase on activation of primary rat HSCs 
and upon its binding to fibronectin, where there is an accumulation of signalling 
proteins and the aggregation of the receptors initiates the ERK (Extracellular signal-
regulated kinase ) and JNK signalling pathways (Milliano and Luxon, 2003). Zhou et al. 
(2004) also reported an increase in the αv and β3 subunits in HSCs cultured on collagen 
I and vitronectin, and that disruption of these receptor subunits resulted in inhibition 
of proliferation and induced apoptosis in these cells. It has also been documented that 
ECM protein receptors play a role in HSC behaviour. Yang et al. (2008) reported that 
LX-2 migratory behaviour towards collagen I was altered in the presence of α1- and α2- 
blocking antibodies indicating these receptors have a role in HSC function. Olsen 
(2012) observed that cellular fibronectin containing the alternatively spliced extra 
domain A (EIIIA), which is upregulated during the wound healing process, increased 
motility in primary rat HSC and that this process required the α9β1 integrin. Priya and 
Sudhakaran (2008) also observed altered HSC behaviour mediated through integrin 
signalling. They reported an increase in apoptosis in HSCs maintained on collagen I 
when treated with curcumin in the presence of an anti-α2β1 antibody when compared 
with those treated with curcumin with no antibody present, suggesting integrins also 
control apoptotic pathways. Activation of HSCs can also be mediated through receptor 
150 
 
activation; Zvibel et al. (2010) reported that L-thyroxine, a synthetic thyroid hormone 
identical to the thyroid hormone-thyroxine, induced activation of primary rat HSCs and 
this could be reversed by antibody blocking of the β3 integrin subunit. In this study we 
observed differences in expression in the α2 and β4 subunits on collagen I, gelatin and 
laminin, as well as α5 on collagen I, and it is possible that integrins containing these 
subunits could be involved in a signalling cascade, which goes on to influence Cygb 
expression in HSC-T6s, as Cygb is also differently expressed at the RNA and protein 
level on different ECM surfaces in these cells (Chapter 5). The results of the receptor 
screen in this study show no significant difference or biological trend in DDR receptor 
expression. DDRs do not recognise gelatin as the triple helix of collagen is required for 
DDR activation (Vogel et al., 2006). It is therefore unlikely that Cygb expression is 
mediated through a DDR signalling pathway as our observations indicate that 
expression of Cygb RNA in HSC-T6 cells is effected by gelatin, along with collagen I and 
laminin. Thus, it is more likely that Cygb RNA expression is modulated via an integrin 
signalling pathway. The observed difference in cell morphology (in HSC-T6 cells) 
proliferation and activation state reported in Chapter 4 are also likely to be regulated 
through integrins, as other authors have reported changes in cell behaviour associated 
with integrin expression and activation, which is discussed above; however, not all 
relevant receptors for ECM proteins in HSC have been screened in this study, and 
although alterations in three of the five integrin subunits screened were observed, 
integrin subunit blocking experiments were not performed, therefore we cannot 
conclude directly that these subunits are responsible for the observed effects on HSC-
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T6s. The possibility remains that the receptor through which signal transduction is 
occurring has not yet been identified.  
Whichever receptor ECM signals through in HSC-T6 cells, it is clear that HSC-T6s 
cultured on collagen I have increased FAK Y397 phosphorylation compared with those 
cultured on laminin and non-coated plastic. FAK is a critical mediator of integrin 
signalling as integrins have no intrinsic enzyme activity (Carver and Goldsmith, 2013) 
and Michael et al. (2009) showed that autophosphorylation of FAK at Y397 is 
important in adhesion strengthening and integrin binding rate, and FAK expression has 
a role in regulating integrin activation in human dermal fibroblasts. It has been shown 
that FAK is upregulated in an in vivo mouse model of liver fibrosis, and the distribution 
of FAK expression correlates with αSMA expression, a marker of activated HSC, in 
these fibrotic livers (Jiang et al., 2004). Shen et al. (2006) demonstrated that FAK can 
mediate proliferation in primary rat HSCs and FAK silencing by short-hairpin RNA can 
reduce proliferation and induce apoptosis in HSC-T6 cells (An et al., 2011). Rodriguez-
Juan et al. (2009) reported similar observations in primary rat HSCs, where silencing of 
FAK by short-interfering RNA increased apoptosis in these cells, they also observed 
that blocking of the α5 integrin subunit prevented FAK phosphorylation by binding of 
fibronectin, linking ECM binding to integrins to FAK phosphorylation in HSCs. The 
observation made in this study that there is an increase in phosphorylated FAK at Y397 
in HSC-T6 cells cultured on collagen I, and these cells show increased proliferation and 
activation state, as analysed by ATRA uptake and αSMA RNA expression, is in line with 
the findings of others, namely that FAK expression and phosphorylation is an 
important event HSC activation and regulates processes in HSC that are associated 
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with their activation, such as increased proliferation and apoptosis (Chapters 4, 5 and 
6) FAK has also been shown to be important in myofibroblast differentiation and 
activity in primary lung fibroblast in mice (Lagares et al., 2012). HSC-T6 cultured on 
collagen I also have decreased Cygb expression, as does the human HSC cell line LX-2 
(Chapter 5), and FAK phosphorylation could have a role in the control of Cygb 
expression in these cells. 
In this investigation, silencing of de novo FAK expression by RNAi was not achieved, 
unlike in the study conducted by An et al. (2011), and therefore no effect on HSC-T6 
behaviour or Cygb expression was observed. Further optimisation of this technique 
needs to be undertaken in order to effectively silence FAK expression, for this study to 
discover if inhibiting new FAK synthesis effects Cygb expression and establish a 
signalling mechanism. But it might not be that de novo FAK expression is the most 
important event in ECM signalling to Cygb, phosphorylation of FAK already present in 
the cell could have a more important role in the signalling mechanism. Inhibition of 
FAK phosphorylation by FAKI has been shown to effect cell behaviour in several 
previous studies. Golubovskaya et al. (2008)showed that treatment with FAKI inhibited 
cell attachment, caused cell detachment and reduced cell viability in BT474 breast 
cancer cells, Hochwald et al. (2009) found similar results in the pancreatic cancer cell 
lines Panc-1 and Miapaca-2 as did Beierle et al. (2010) in neuroblastoma cell lines, 
indicating FAKI has anti-tumour activity. Anti-angiogenic activity of FAKI has also been 
observed in human umbilical vein endothial cells (HUVEC), where FAKI treatment 
impaired HUVEC viability induced apoptosis, impaired cell migration and blocked FAK 
autophosphorylation (Cabrita et al., 2011). This study reports decreased cell viability 
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and inhibition of FAK phosphorylation in HSC-T6s at concentrations below 1 µM, this is 
much lower than the concentrations required for inhibition of phosphorylation in 
HUVECs (5 µM) (Cabrita et al., 2011) and the cancer cell lines studied (10 µM) (Xu et 
al., 2005, Hochwald et al., 2009, Beierle et al., 2010), suggesting that HSC-T6s could be 
more sensitive to this treatment than endothelial cells or cancer cells.   
Unfortunately investigation of the effects of inhibition of FAK phosphorylation on Cygb 
expression by western blot and RT-PCR proved inconclusive. RT-PCR analysis showed 
no effect of FAKI on Cygb expression in either cells cultured on non-coated plastic or 
collagen I; however western blot suggests that Cygb protein expression is 
reconstituted by FAKI treatment. Confusingly, there is also no effect of culture on 
collagen I on Cygb in these cells, this could be caused by the effects of continuous cell 
culture on cell phenotype, incorrect coating of collagen I on tissue culture plates or 
collagen I stocks being beyond their use-by date. It is also possible that the FAKI stocks 
had gone-off due to too many freeze-thaw cycles, hence no effect on Cygb was 
observed as potency might have been lost. In contrast, western blot analysis of Cygb 
protein expression seems to indicate a recapitulation of expression in HSC-T6s treated 
with FAKI, implying a signalling link between FAK phosphorylation and Cygb 
expression, therefore further experiments are required resolve this issue. It has not 
been possible to establish this link with certainty over the course of this investigation, 
however the findings of this study and the implications of discovering a link between 
ECM signalling to Cygb expression in HSCs, possibly occurring through FAK 
phosphorylation is discussed in Chapter 7. 
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7.1 General Discussion 
 
Chronic liver disease is of increasing concern in the UK and Europe, accounting for 2% 
of deaths in England, with a rise of 25% in deaths in England between 2001 and 2009. 
In Europe; liver cirrhosis is the cause of around 170,000 deaths, and liver cancer 47,000 
deaths, per annum and 29 million people suffer from a chronic liver condition, which is 
comparable with other diseases that have a high degree of public and media attention, 
such as breast cancer (Effiong et al., 2012, Blachier et al., 2013). All chronic liver 
diseases can induce fibrosis in the liver, ultimately leading to cirrhosis, and the recently 
discovered globin, Cygb has been implicated within the fibrotic process in fibrosing 
diseases (Kristensen et al., 2000, Nakatani et al., 2004, Schmidt et al., 2004, Zion et al., 
2009, Mimura et al., 2010, He et al., 2011, Cui et al., 2012, Singh et al., 2013). Within 
liver disease it is widely accepted that HSCs are the major effectors of hepatic 
fibrogenesis and HSC activation is the dominant profibrotic pathway (Friedman, 2008b, 
Friedman, 2008c). Cygb expression in the liver has been reported to be specific to 
HSCs, however this observation is disputed, with some reports of expression in 
hepatocytes (Kawada et al., 2001, Geuens et al., 2003, Yang et al., 2011, Motoyama et 
al., 2014). Whatever its cellular expression, there are many reports that Cygb is 
upregulated in liver disease, both in murine models and in diseased human liver 
(Kristensen et al., 2000, Schmidt et al., 2004, He et al., 2011, Cui et al., 2012, 
Motoyama et al., 2014). Data presented in this thesis confirm this observation in 
murine models of liver disease and in human liver tissue from different disease 
aetiologies, staining for CYGB was also observed in hepatocytes in both normal and 
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diseased tissue, but was more strongly associated with fibrotic regions, where HSCs 
accumulate, than hepatocytes in the diseased samples (Chapter 3). 
One of the key changes in the liver during chronic injury is the accumulation and 
change in composition of ECM (Benyon and Iredale, 2000) and HSC are critical 
mediators in this process (Friedman, 2008b). Many studies have shown that ECM can 
affect HSC behaviour via outside-in signalling (Davis, 1988, Friedman et al., 1989, Gaca 
et al., 2003, Friedman, 2008c, Yang et al., 2008). Presented in Chapters 3 and 4 of this 
study is further evidence that different ECM proteins can effect HSC morphology, 
proliferation and activation state, with collagen I, an important component of the 
hepatic scar, conferring a more activated phenotype on HSCs, and laminin, a major 
constituent of ECM in a normal liver, promoting a more quiescent phenotype. Also 
presented in Chapter 5 is the novel observation that Cygb expression in HSCs at the 
RNA and protein level is effected by ECM. Surprisingly, Cygb expression was down 
regulated in HSCs, which had a more activated phenotype, contrary to several previous 
reports of Cygb upregulation in activated HSCs (Kristensen et al., 2000, Kawada et al., 
2001). However, consistent with our data, more recent research has suggested that 
Cygb has an antifibrotic effect, Thuy et al. (2011) found increased tumorigenesis 
(which is related to hepatoxicity and subsequent increase in fibrosis) in DEN treated 
Cygb knockout mice, and Cui et al. (2012) found that arundic acid attenuated fibrosis, 
and observed a corresponding increase in Cygb expression. Therefore, our observation 
that activated HSCs have reduced Cygb expression is entirely consistent with these 
more recent reports.  
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Signalling from the ECM to cells occurs via cell surface ECM receptors, predominantly 
integrins (Benyon and Iredale, 2000, Bedossa and Paradis, 2003), integrin signalling 
though cell attachment to ECM has been found to influence gene expression and 
behaviour (Carloni et al., 1996, Miranti and Brugge, 2002), (Zhou et al., 2004), (Streuli, 
2009). Data presented in this report show differential expression of integrin subunits in 
cells cultured on different ECM proteins, this observation is in agreement with findings 
from Zhou et al. (2004) who also reported differential expression of integrin subunits 
in HSCs on different ECM proteins. Transduction of the signal from ECM through 
integrins occurs through integrin clustering and activation, the formation of focal 
adhesions and the autophosphorylation of FAK (Leitinger, 2003, Desgrosellier and 
Cheresh, 2010). Chapter 6 of this study presents data that shows increased FAK 
phosphorylation in HSC-T6 cells cultured on collagen I compared with those cultured 
on non-coated plastic or laminin. HSCs cultured on collagen I have a more activated 
phenotype (Chapters 3 and 4) and the observation that these cells have increased 
pFAK Y397 is in line with the observations of others who have observed an 
upregulation of pFAK in fibrotic livers (Jiang et al., 2004) and that FAK can mediate 
stellate cell behaviour (Shen JG et al., 2006, Rodriguez-Juan et al., 2009, An et al., 
2011). 
We were unable to directly confirm a link between FAK Y397 phosphorylation and 
Cygb expression in this report (Chapter 6). However a link between FAK signalling and 
Cygb expression is feasible and this is the subject of on-going research in our 
laboratory. There are several known signalling pathways mediated through FAK 
phosphorylation that could impact Cygb expression through effecting transcription 
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factor expression and activity, some of which have binding sites in the promoter region 
of the Cygb gene, for example, NFAT, AP-1 and HIF-1 are known to positively regulate 
Cygb transcription under hypoxic conditions (Singh et al., 2009), some of these 
pathways are depicted in Figure 7.1. FAK phosphorylation also modulates ROS 
generation through activation of the RAC-1 (Ras-related C3 botulinum toxin substrate-
1), a member of the Rho GTPase family. RAC-1 activation increases intracellular ROS, 
and as discussed in section 1.1.6.2, Cygb might have a role in ROS scavenging, or as 
part of a signalling cascade involving ROS modulation, therefore Cygb could be 
involved in the RAC-1 pathway, affecting levels of intracellular ROS. Nimnual et al. 
(2003) demonstrated that a RAC-mediated increase in intracellular ROS in the rat 
embryonic fibroblast cell line, REF52, caused downregulation of Rho GTPase. Early in 
the research into Cygb, Nakatani et al.(2004) speculated that Cygb overexpression in 
the NIH3T3 mouse fibroblast cell line could induce the activation of Rho owing to the 
observed formation of actin stress fibres and focal contacts, for which Rho activation is 
critical (Ridley and Hall, 1992), in these cells. Rho activation has also been shown to 
inhibit migration in NIH3T3 cells (Olivo et al., 2000). HSC-T6 cells cultured on laminin 
show increased Cygb expression and decreased proliferation, and the opposite is true 
for HSC-T6 cells cultured on collagen I, which is in line with observations of impaired 
cell migration in Cygb overexpressing cells made by Nakatani et al.(2004). RAC and Rho 
GTPases are known to be critical for signal transduction from extracellular sources to 
cytoskeletal rearrangement (Etienne-Manneville and Hall, 2002). An increase in RAC 
results in an increase in ROS, which, in turn, causes increased spreading and migration, 
in contrast, an increase in Rho induces increased contractility and adhesion, and Rho 
159 
 
can be negatively regulated by RAC, as was shown by Nimnual et al. (2003). Data 
presented in Chapter 5 of this thesis show that HSC-T6 cells cultured on collagen I have 
increased intracellular ROS, and these cells have decreased Cygb expression. Cells 
cultured on laminin, where Cygb is increased, do not have increased levels of 
intracellular ROS, therefore, redox regulation of this pathway could be influenced by 
cellular levels of Cygb, which might regulate ROS and have a regulatory role in the RAC 
signalling pathway, this is depicted in Figure 7.2 A and B. Other work in our laboratory 
has also suggested a role for CYGB in the motility of cancer cells, with CYGB 
overexpression in head and neck cancer cell lines reducing cell motility and 
intracellular ROS levels (Dr. Hodges, personal communication), which is further 
evidence for a potential role for CYGB in this signalling pathway. 
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Figure 7.1: Signalling pathways from focal adhesion kinase (FAK) phosphorylation (P) to transcription 
factors known to have binding motifs present in the CYGB promoter region, and also effecting reactive 
oxygen species (ROS) generation. NFAT binding to the CYGB is known to promote CYGB transcription (Singh 
et al., 2009)  
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Figure 7.2: Possible signalling pathways linking A) RAC-1 activation and ROS (reaction oxygen species) 
generation and Rho downregulation and increased cell spreading and migration and B) Rho activation and 
RAC-1 downregulation and increased cell contractility and adhesion, indicating possible regulation of these 
pathways by Cygb. 
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Figure 7.3: Possible signalling pathway between ECM and Cygb expression through integrin activation, 
FAK phosphorylation to Cygb expression, impacting on cell behaviour and possibly going through the RAC 
signalling pathway. 
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Thus, Cygb could have a role in modulating intacellular ROS, in turn affecting the RAC/Rho 
signalling pathway and impacting on cell migration and adhesion, a diagram presenting the 
overall hypothesis of ECM signalling through integrin activation and FAK phosphorylation to 
Cygb expression, HSC activation and cell proliferation is depicted in Figure 7.3. Work in our 
laboratory is continuing to investigate this signalling pathway and establish the link between 
ECM and Cygb expression. 
 
7.2 Future work 
 
The most important aspect of future work on this project is the confirmation of a direct link 
between ECM signalling and Cygb gene expression, which was explored in Chapter 6. 
Differential integrin expression in HSC-T6 cells cultured on different ECM proteins was 
observed. To discover if signalling from ECM to Cygb occurs through integrins, and to 
establish the start of the signalling cascade, expression of all integrin subunits would need 
to be undertaken. To find out which integrin subunit or subunits are pivotal in signal 
transduction to Cygb expression, blocking or knockdown experimants also need to be 
conducted, looking at the effect of blocking integrins on Cygb expression. 
The most important observation in Chapter 6 is the difference in FAK pY397 expression 
between HSC-T6 cells cultured on collagen I and those cultured on laminin or non-coated 
plastic, leading to hypothesis that signalling from ECM to Cygb is dependent on FAK 
phosphorylation. However, confirmation of this link was not established in this 
investigation, therefore, work is continuing to see whether FAK phosphorylation impacts 
Cygb expression through pFAK inhibition experiments and RT-PCR analysis of Cygb 
expression. Investigations by others in our laboratory are also focusing on the link between 
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Rho kinase, CYGB expression and cell behaviour in terms of attachment and proliferation, to 
determine if CYGB is indeed involved in the signalling pathways outlined in Figure 7.2. 
Other important aspects, which were outside the scope of the current study, are the 
observations of the reciprocal nature of Cygb and αSMA gene expression and the finding 
that laminin has the opposite effect to collagen I. Further investigations into the effects of 
laminin along the lines of those carried out in Chapter 5 on collagen I, such as a time course 
of expression and influence of attachment to the surface would be interesting. Also, 
increased levels of pFAK were not observed in HSC-T6 cells cultured on laminin, therefore 
no potential signal transduction mechanism has been indentified in this circumstance. 
Further investigation into signalling from laminin to Cygb expression should be undertaken, 
to establish if it is a different mechanism from collagen I, or whether the two pathways 
overlap in HSC-T6 cells. Also, differences between ECM receptor signalling in the HSC-T6 cell 
line and the LX-2 cell line, and differences in this signalling pathway between rat and human 
HSCs should be further investigated, as laminin has no effect on Cygb expression in LX-2 
cells, this difference is important as it has implications for the translation of this research 
from in vitro models into in vivo models and also studies in human tissue.  
Investigations into the effects of gelatin should be undertaken, to establish how this protein, 
which is not known as a biological ECM substrate, is having an influence which is greater 
than collagen I on HSC-T6 cells. Experiments similar to those carried out on HSC-T6 cells 
cultured on collagen I should be done to discover if signalling from gelatin occurs along the 
same pathway as collagen I. 
Finally repetition of all experiments should be conducted in primary HSCs. Due to lack of 
resources, investigations into the effect of ECM on Cygb in primary stellate cells were 
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difficult to conduct and were often unsuccessful, but the major limitation of this project is 
that the model has not been confirmed in primary cells, and therefore it is not known 
whether the data presented here are an artefact cell immortalisation or a real effect that 
translates to primary cells. This is important for the implications of these findings on future 
research.  
In summary, reported in this thesis is the novel observation that Cygb expression in an in 
vitro model of HSC can be modulated by ECM. This discovery could have important 
implications for the understanding of the progression of liver fibrosis, and provide a new 
target for the treatment and reversal of liver fibrosis. 
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Appendix 1: Immunomatched controls for CYGB IHC 
 
 
 
Appendix 1: Immunomatched controls for section staining for CYGB expression Abbreviations: NASH = non-alcoholic 
fatty liver disease, PBC = primary biliary cirrhosis, PSC = pulmonary sclerosing   cholangitis, ALD = alcoholic liver 
disease, AIH = autoimmune hepatitis. N=1
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Appendix 2: HSC-T6s grown on non-coated plastic, collagen I and laminin (see attached CD) 
 
Appendix 3: LX-2s grown on non-coated plastic, collagen I and laminin (see attached CD) 
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Appendix 4: Results of non-significant (p >0.05) ECM receptor expression by RT-PCR 
 
  
 
 
 
 
Appendix 4 : Expression of A) α6, B) α11, C) β1, D) β3, E) DDR1 and F) DDR2 integrin subunit ECM receptors 
across laminin, collagen I and gelatin ECM proteins in HSC-T6 cells relative to the expression levels of those 
grown on non-coated T25 culture flasks. N=3 
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Appendix 5: Results of RNAi optimisation  
 
 
 
 
 
 
Appendix 5: RNAi treatment of PKt2 (FAK) in HSC-T6 cells seeded at A) 50,000 cells/ml, B) 100,000 cells/ml 
and C) 200,000 cells/ml cultured for 48hrs on non-coated plastic with 24hrs RNAi then analysed for PKt2 
expression by RT-PCR. N=1 
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Appendix 6: Western blot of FAK pY397 protein expression in HSC-T6s after 48hrs of 
treatment with FAKI 
 
 
 
 
 
 
 
 
 
 
 
Appendix 6: Western blot for protein expression of phosphorylated FAK Y397 in cells cultured for 48hrs non-
coated tissue culture plastic and collagen I and treated with FAKI for A) 24hrs and B) 48hrs. 
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